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ABSTRACT 
Prions accumulate in the lymphoreticular system (LRS) at early stages of prion disease, 
long before they are detected in the brain. A considerable body of evidence showed 
that both haematopoietic and stromal cells play a role in prion pathogenesis. However, 
the contribution of different cell types to the accumulation and the spread of prions in 
the LRS are not well understood. Taking advantage of a quantitative in-vitro infectivity 
assay, the Scrapie Cell Assay (SCA) and high density magnetic-activated cell sorting 
(MACS), we studied the kinetics of prion accumulation in various splenic cell types at 
early stages of prion disease. The determination of statistically robust infectious titres 
was achieved by statistical modelling using generalised linear model (GLM) regression. 
With this novel procedure time-dependent changes of prion titres were monitored in 
seven distinct splenic cells and identified two cell types that have previously not been 
associated to prion pathogenesis, plasmacytoid dendritic (pDC) and natural killer (NK) 
cells. Notably, in Prnp-/- mice, e.g. in absence of prion replication, infectivity was 
detected in macrophages and dendritic cells (DC) after 3 dpi, but not in lymphocytes, 
underscoring the importance of prion sequestration by antigen-presenting cells which 
are among the first cells of the immune system to encounter pathogens. Reports of the 
secretion of endosome-derived membrane particles, so called exosomes by immune-
competent cells and prion-infected cell lines raised the question whether prion 
secretion could be a potential route for the spread of prions. We here present the first 
evidence that MACS-isolated lymphocytes and DCs from scrapie-infected mice secrete 
prions which are associated to the release of exosome-like membrane particles into the 
cell culture supernatant ex vivo. 
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INTRODUCTION 
1.1 Transmissible spongiform encephalopathies 
Transmissible spongiform encephalopathies (TSE) or prion diseases are a group of 
lethal neurodegenerative diseases that affect humans and other animal species. 
Examples are Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker (GSS), 
and kuru in humans, bovine spongiform encephalopathy (BSE) in cattle, scrapie in 
sheep and chronic wasting disease (CWD) in cervids. TSEs are characterized by long 
disease incubation times followed by a rapidly progressing and severe degeneration. 
Spongiform degeneration, astrocyte and microglia proliferation, and deposition of 
misfolded proteins are the main characteristic histopathological features of prion 
diseases (Kretzschmar, 1993).  
Although prion diseases are rare transmissible diseases with a prevalence of one case 
per million people each year1
The nature of the infectious agent distinguishes TSEs from all known infectious diseases 
and renders them to date a unique biological phenomenon. According to the broadly 
accepted ‘protein-only’ hypothesis the infectious agent is devoid of nucleic acids and 
consists mainly, if not entirely of protein (Griffith, 1967). An abnormal conformer of a 
, they made international headlines during the European 
BSE crisis in the 1990s. With hundreds of thousands of infected cattle and the risk of a 
foodborne transmission to humans, prion diseases have caused massive economic 
losses and form a public health concern. Although the BSE crisis has been largely 
resolved, a recent increase in the number of cases of CWD and first cases of BSE in the 
United States (Belay et al., 2004; Richt et al., 2007; Aguzzi et al., 2008), renders these 
diseases a current topic, but also a fascinating one, given the uniqueness of the  biology 
of prions. 
                                                 
1 World Health Organization (WHO). http://www.who.int/zoonoses/diseases/prion_diseases/en/    
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host membrane glycoprotein known as the prion protein was identified as a major 
component of the infectious agent (Prusiner, 1982). How a protein can be transmissible 
and encode for different conformational variants is still unresolved and remains a 
matter of debate.  
Another remarkable feature of prions is that they fail to induce an immune response in 
the host. But surprisingly, the immune system plays an important role in prion 
pathogenesis and is possibly involved in the accumulation, replication of prions and 
their transport to the brain (Aucouturier and Carnaud, 2002; Aguzzi et al., 2008).  
1.2 Nature of the infectious agent 
1.2.1 The ‘protein-only’ hypothesis 
Early observations led to the conclusion that TSEs are unconventional infectious 
diseases, since their disease-causing agents are resistant to procedures that inactivate 
nucleic acids, but are sensitive to procedures that inactivate proteins (Alper et al., 
1967; Alper et al., 1978; Prusiner, 1982). In 1967, Griffith suggested that the 
transmissible agent is an infectious protein that is propagated by autocatalytic 
misfolding. The nature of the TSE agent was defined in more detail by Prusiner in 1982, 
who coined the term ‘prion’ for proteinaceous infectious particle (Griffith, 1967; 
Prusiner, 1982). Purification protocols for the infectious agent in hamster brain 
homogenates led to the detection of a 27-30 kDa protease resistant protein, the 
PrP27-30 (Bolton et al., 1982; Prusiner et al., 1982). This protein, the protease-resistant 
core of a 33-35 kDa protein designated PrPSc, was suggested to be a major constituent 
of the infectious fraction. Further research conducted in the laboratories of S. Prusiner 
and C. Weissmann led to the discovery that PrPSc is encoded by a host gene (Basler et 
al., 1986). Both PrPSc and the normal cellular prion protein, PrPC are encoded by a 
single gene and share the same amino acid sequence (Oesch et al., 1985; Basler et al., 
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1986; Stahl and Prusiner, 1991). PrPSc and PrPC are conformational variants of the same 
protein that differ in their biochemical properties. While PrPC is predominately 
α-helical, soluble and protease sensitive, PrPSc has a higher β-sheet content, forms 
insoluble aggregates and is partially resistant to proteinase K (PK) (Stahl and Prusiner, 
1991; Caughey et al., 1991; Riek et al., 1997).  
According to the ‘protein-only’ hypothesis, the replication of misfolded protein results 
from the recruitment by PrPSc of endogenous PrPC monomers and their conversion into 
PrPSc by a conformational change (Griffith, 1967; Prusiner, 1982). The most widely 
accepted model of prion propagation, the seeded polymerization model, postulates 
that PrPSc conformers are stabilized by recruitment into a stable PrPSc seed which 
accelerates the addition of monomers. Prion propagation is driven by the 
fragmentation of large PrPSc aggregates resulting in more infectious PrPSc seeds 
(figure 1.1 A) (Come et al., 1993). Oligomers of 14 to 28 PrP molecules were reported 
as the most infectious entities (Silveira et al., 2005). The aetiology of sporadic and 
inherited prion diseases can also be explained with this model, since PrP mutations 
could alter the PrPC ↔ PrPSc equilibrium and favour nucleation (Jarrett and Lansbury, 
1993).  
A wealth of evidence supports the ‘protein-only’ hypothesis as exemplified by the 
following: Abrogation of PrPC prevents prion disease (Bueler et al., 1993; Brandner et 
al., 1996a; Blattler et al., 1997), certain PrP gene mutations have been linked to 
inherited prion diseases (Hsiao et al., 1992) and conversion of PrPC into PK resistant PrP 
(PrPres) can be recapitulated in cell-free systems using PrPSc seeds in large excess, a 
process that is species-specific (Kocisko et al., 1994; Kocisko et al., 1995). A number of 
recent reports demonstrate the de-novo generation of prions from recombinant prion 
protein, albeit at extremely low titres (Wang et al., 2010; Colby et al., 2010).  
Historically, the presence of distinct prion strains constituted the main argument 
against the ‘protein-only’ hypothesis (Weissmann, 1991), but the coexistence of 
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distinct conformational variants whose clonal selection is favoured by unknown host 
factors could resolve this paradox (Collinge and Clarke, 2007). Prion strains are defined 
by their characteristic incubation periods, biochemical properties and 
neuropathological features. According to our current understanding prion-strain 
features are encoded as PrPSc oligomers with different conformations and glycosylation 
patterns (figure 1.1 B). Structural information is propagated by recruitment of PrP 
monomers (in a strain-specific manner) into pre-existing PrPSc conformers which serve 
as templates (Bessen et al., 1995; Khalili-Shirazi et al., 2005). Differences in the 
aminoacid sequence of PrPC between animal species may define what conformations 
can be acquired; the overlap of permitted PrPSc conformers between species could 
explain the efficiency of transmission and the species barrier effect (Collinge and 
Clarke, 2007). 
 
 
Figure 1.1 (A) Model for prion propagation. PrP fluctuates between the native state and a minor 
misfolded conformation, which self-aggregates into a stable PrPSc seed (nucleation). Once the seed is 
formed, addition of new monomers occurs rapidly. (B) Molecular strain typing of human prions. 
Different prion strains can be distinguished by their biochemical properties such as the size of protease-
resistant core, revealed by distinct mobilities and ratios of di-, mono- and un-glycosylated forms. 
Variant CJD (T4) is characterised by a diglycosylated-dominant PrPSc pattern and is readily distinguishable 
from strains associated with sporadic and iatrogenic CJD (T1-3). Reproduced from the J. Neurol. Neurosurg. 
Psychiatry, Collinge, J., 2005, Vol 76, pp 906-919 (Collinge, 2005). 
A B
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1.2.2 PrPSc as a surrogate marker for infectivity 
Studies by Bolton et al. with 263K hamster scrapie led to the identification of PrPSc as a 
major component of the infectious isolates (Bolton et al., 1982). A strong correlation 
between PrPSc and infectivity was inferred from experiments that showed a 
proportional relationship between infectious titres and the concentration of PrP27-30, 
the protease resistant core of PrPSc (Bolton et al., 1982; Gabizon et al., 1988). However, 
formation of PrPSc does not always correlate with infectivity and several results have 
challenge the hypothesis that PrPSc is the TSE agent. Prion diseases are transmitted in 
the absence of detectable levels of PrPSc (Sakaguchi et al., 1993; Lasmezas et al., 1997; 
Barron et al., 2007). Likewise, abnormal deposits of PrP were detected in the absence 
of infectivity (Piccardo et al., 2007). Relatively protease-sensitive forms of PrP were 
identified in atypical cases of scrapie in sheep (Nor98) and cattle (BASE) (Everest et al., 
2006; Benestad et al., 2008) indicating that both protease-sensitive (sPrPSc) and 
protease-resistant (rPrPSc) conformers may co-exist (Taraboulos et al., 1992; Safar et 
al., 1998; Tzaban et al., 2002). PrPSc, defined by its partial resistance to proteases 
should therefore be considered a surrogate marker for prions. Although in most cases 
rPrPSc correlates with infectivity, the determination of PrPSc levels cannot be used in 
quantitative terms to determine infectious titres and infectivity assays remain the gold 
standard. Until recently, infectivity assays were based on the transmission of prions to 
laboratory animals, which are time consuming and inaccurate. An important 
improvement in titre determination is the establishment of cell-based infectivity assay, 
e.g. the scrapie cell assay (SCA), developed for measuring de novo infectivity (Klohn et 
al., 2003). Unfortunately, most known prion-replicating cell lines are only susceptible to 
murine prions, which limit their application for diagnostic purposes. An interesting 
application of in vitro infectivity assays has recently been published by Mahal et al. 
where different strains could be distinguished in cell culture using a panel of 
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susceptible cell lines with different responses to various mouse prions (Mahal et al., 
2007).  
Limitations of infectivity assays in regards to assay duration and prion susceptibility to 
multiple prion strains render PrPSc detection on Western Blot the method of choice for 
the diagnosis of prion diseases in humans and ruminants. To improve detection of PrPSc 
in tissues and clinical diagnosis, procedures like the selective precipitation of PrPSc by 
sodium phosphotungstic acid (NaPTA) or the amplification of PrPSc by protein 
misfolding cyclic amplification (PMCA) have been used (Safar et al., 1998; Wadsworth 
et al., 2001; Castilla et al., 2005b).  
1.2.3 PrPC trafficking and PrPSc formation 
Clear experimental evidence confirms that PrPC expression is a prerequisite for prion 
propagation (Bueler et al., 1993; Brandner et al., 1996a) and subsequent 
neurodegeneration (Brandner et al., 1996b). A better understanding of the function 
and cell biology of PrP are essential to characterise molecular events that trigger prion 
formation.  
The prion protein is a highly conserved cell surface glycoprotein abundant in neurons 
and glia, but also expressed in other cells types including immune cells (Aguzzi and 
Polymenidou, 2004). Although numerous studies have identified a role of PrPC in cell 
signalling, copper metabolism, resistance to oxidative stress, immuno-regulation and 
synaptic transmission, the functional role of PrPC remains largely unknown (reviewed in 
Martins et al., 2002). Interestingly, despite its highly conserved aminoacid sequence, 
PrPC seems to be dispensable, since no obvious phenotypic changes were observed in 
PrP-knockout mice (Bueler et al., 1992) and in mice after the postnatal ablation of the 
PrP gene in neurons (Mallucci et al., 2002).  
PrPC is a glycosyl-phosphatidylinositol (GPI)-anchored glycoprotein (Stahl et al., 1987), 
attached to the outer leaflet of the lipid membrane and is associated with lipid rafts, 
CHAPTER 1  Introduction 
 23 
i.e. membrane domains rich in cholesterol and sphingolipids. Synthesised in the rough 
endoplasmic reticulum (ER), PrPC is transported via the Golgi to the plasma membrane. 
PrPC is post-translationally modified by addition of N-linked oligosaccharide chains, the 
formation of a disulphide bond and the attachment to the GPI anchor (Taylor and 
Hooper, 2006). Following its transport to the membrane, newly synthesised PrPC is 
rapidly internalised and recycled constitutively between the plasma membrane and the 
endocytic compartment (Shyng et al., 1993). The conversion of PrPC into PrPSc seems to 
occur after newly formed PrPC reaches the membrane, either at the surface or after 
internalisation, as supported by the observation that blocking the transport to the 
plasma membrane or inhibition of endocytosis prevents PrPSc formation (Borchelt et 
al., 1992; Taraboulos et al., 1992; Marijanovic et al., 2009). Different internalisation 
pathways have been suggested including caveolae- and clathrin-mediated processes 
(reviewed in Prado et al., 2004; Campana et al., 2005) (figure 1.2). Internalisation of PrP 
through caveolae was shown for Chinese hamster ovary cells (Vey et al., 1996; Peters et 
al., 2003), whereas in neuronal cells PrPC clustered in clathrin-coated vesicles as shown 
by immunogold detection in vitro and in vivo (Shyng et al., 1994; Shyng et al., 1995; 
Sunyach et al., 2003). The mechanism by which PrPC is internalized remains unclear and 
may be cell- or tissue-specific. Irrespective of the internalisation pathway, proteins like 
PrPC are directed to early endosomes from where they enter the endosomal recycling 
compartment and are delivered back to the membrane. Alternatively, if targeted for 
degradation, proteins are sorted into multivesicular bodies (MVB) and lysosomes 
(Maxfield and Mcgraw, 2004). 
Despite experimental evidence for PrPSc formation in recycling endosomes it remains 
controversial whether this compartment constitutes the principal site of prion 
conversion (Borchelt et al., 1992; Campana et al., 2005; Marijanovic et al., 2009). A role 
of the ER in PrP conversion was proposed for familial prion diseases where mutant PrP 
misfolds as it is synthesized (Harris, 2003). Furthermore, it was suggested that 
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retrograde transport of surface PrPSc to the Golgi and the ER could interfere with newly 
synthesized PrPC and prime its conversion (Beranger et al., 2002). Plasma membrane, 
endosomal recycling compartment, Golgi, late endosomes, lysosomes and exosomes 
were all shown to accumulate PrPSc (McKinley et al., 1991; Arnold et al., 1995; Sunyach 
et al., 2003; Fevrier et al., 2004; Barmada and Harris, 2005; Marijanovic et al., 2009). 
 
 
Figure 1.2 Endocytosis and subcellular localisation of PrPC. After its synthesis in the ER and transport to 
the membrane through the Golgi, PrPC is internalized. Several pathways may be involved in PrPC 
endocytosis that may vary between cell types (Fivaz et al., 2002). Clathrin-dependent endocytosis 
requires translocation of PrPC to non-raft regions before internalisation. Caveolin dependent and non-
clathrin non-caveolae endocytosis were also suggested. After internalisation PrPC transits through 
endosomes and lysosomes. PrPC in late endosomes or MVBs could be secreted as exosomes. Reproduced 
from the Physiol. Rev., Linden R. et al., 2008, Vol 88, pp 673-728 (Linden et al., 2008). 
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1.3 Pathogenesis of prion diseases 
Acquired forms of TSE are characterized by long incubation times during which prions, 
invisible to the host immune defences (Kasper et al., 1982), travel from the peripheral 
sites of infection to sites of replication in the lymphoreticular system (LRS) and 
ultimately to the central nervous system (CNS). A thorough understanding of early 
events in prion pathogenesis in the LRS is of great interest, since it opens the possibility 
for therapeutic intervention and early diagnosis before clinical symptoms are manifest.  
1.3.1 The immune system in prion diseases 
The involvement of lymphoid organs in prion pathogenesis has been known for a long 
time. In most prion diseases, including variant CJD (Hill et al., 1999; Bruce et al., 2001), 
natural scrapie (Hadlow et al., 1982; van Keulen et al., 1996) and CWD (Sigurdson et al., 
2002), prions are detected in the LRS where they accumulate and replicate before they 
reach the CNS (Eklund et al., 1967; Fraser and Dickinson, 1970). Still, the importance of 
the lymphoid route in prion pathogenesis greatly varies among animal species and 
seems to be strain-specific (Aguzzi and Heikenwalder, 2005). For example, PrPSc was 
detected in the spleens of all vCJD cases, but only in 30 % of sporadic CJD cases (Glatzel 
et al., 2003) and even less in BSE (Somerville et al., 1997).  
Even though rodents are broadly used to characterise the prion colonisation of 
different lymphoid organs and the CNS following different routes of inoculation, it 
should be noted that most natural prion diseases occur in ruminants. Differences 
between the distribution and dissemination of prions may be relevant. Experimental 
limitations when working with natural cases, however, renders mouse models a 
necessary option. The spleen and lymph nodes are the first sites of prion replication 
after peritoneal, cutaneous or intravenous inoculation, while after oral inoculation 
prions accumulate first in Peyer’s patches of the gut-associated lymphoid tissue (Eklund 
et al., 1967; Fraser and Dickinson, 1970; Kimberlin and Walker, 1979; Kimberlin and 
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Walker, 1989a; Kimberlin and Walker, 1989b; Bueler et al., 1993). In particular, disease-
specific deposits of PrP are detected in the germinal centres of lymphoid organs in vCJD 
and scrapie cases associated to follicular dendritic cells (van Keulen et al., 1996; Hill et 
al., 1999). Only after the establishment of infectivity in the LRS are prions detectable in 
the CNS. Sympathetic nerves which innervate lymphoid organs and parasympathetic 
nerves are thought to be main sites for the entrance of prions from the LRS to the brain 
(Kimberlin and Walker, 1980; McBride and Beekes, 1999; Glatzel et al., 2001) 
(Figure 1.3). That this early accumulation in the LRS is essential and precedes 
neuroinvasion has been demonstrated by targeted interventions of the immune system 
where the susceptibility of the host to prions is greatly altered. Disease is significantly 
delayed in mice with impaired immune system, e.g. SCID, RAG, and µMT after 
peripheral prion inoculation (Klein et al., 1997). Similar effects were observed after 
treatments aimed to stimulate or inhibit the immune system (Outram et al., 1974; 
Dickinson et al., 1978; Mabbott et al., 2000). Susceptibility to oral infection was also 
shown to depend on the number of Peyer’s patches present in the ileum (Outram et 
al., 1974). Likewise, splenectomy resulted in prolonged incubation times and delayed 
the infection of the spinal cord (Kimberlin and Walker, 1989b).  
Following oral inoculation, a natural route for prion transmission in acquired TSE forms, 
prions first replicate and colonise the LRS, a process that is critical for the manifestation 
of prion disease. The identification of the cell types and mechanisms involved in the 
uptake, dissemination, accumulation and replication of prions in the LRS is essential to 
identify potential targets for therapy. Early research to address the cellular distribution 
of prions in the LRS showed that both, haematopoietic and stromal compartments are 
involved in the spread and replication of prions. Using cell separation techniques, 
based on density gradient centrifugation, high prion titres were found to be associated 
to low density cells like macrophages, myeloblasts and lymphoblast (Lavelle et al., 
1972; Kuroda et al., 1983). A critical role of the stromal compartment was inferred from 
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early experiments, where ten-fold higher infectious titres were detected in the stroma 
as compared to the pulp fraction of the spleen (Clarke and Kimberlin, 1984). In 
addition, sublethal whole body γ-irradiation of mice before or after inoculation with 
prions, which eliminates actively dividing haematopoietic cells, had no effect on the 
disease incubation time for the ME7 strain (Fraser and Farquhar, 1987). The 
contribution of macrophages, B cells, dendritic cells (DC) and follicular dendritic cells 
(FDC) in prion dissemination and replication are discussed in the next sections.  
 
 
Figure 1.3 Peripheral prion pathogenesis. Following oral infection, prions accumulate in lymphoid 
organs, like the spleen, lymph nodes and Peyer’s patches. Macrophages, lymphocytes and DCs are 
potential candidates for the transport of prions to the peripheral nervous system. From the sites of 
infection prions travel to the lymphoid organs and to the peripheral nervous system, alternatively, direct 
invasion of the CNS might occur after peripheral infection. Replication of prions in the lymphoid organs 
requires FDCs and B cells. Prions reach the brain via sympathetic and parasympathetic nerves where 
neuronal damage occurs. Reproduced from the Nat. Rev. Mol. Cell Biol., Aguzzi A. et al., 2001, Vol 2, pp 118-126 
(Aguzzi et al., 2001). 
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1.3.2 Peripheral replication of prions 
Although pathology of prion disease is confined in the central nervous system (CNS), 
lymphoid organs, particularly the spleen and lymph nodes, accumulate infectivity and 
PrPSc long before they are detectable in the CNS (Eklund et al., 1967; Kimberlin and 
Walker, 1989b). The reduced susceptibility of immuno-deficient mice to scrapie after 
peripheral but not intracerebral inoculation, illustrates the importance of prion 
replication in the LRS for neuroinvasion. Mice with severe combined immunodeficiency 
(SCID) which lack lymphocytes and mature FDCs were in general resistant to peripheral, 
inoculation (O'Rourke et al., 1994). Importantly, susceptibility and accumulation of 
infectivity in the spleen of SCID mice was restored by reconstitution with immuno-
competent cells (Fraser et al., 1996). Several mouse models helped to identify the cell 
types involved in prion replication and neuroinvasion, i.e. immuno-deficient mice, 
knockout mice lacking specific components of the immune system and chimeric mice 
where PrP expression was restricted to the stroma or haematopoietic compartment.  
That T cells are dispensable for prion pathogenesis was first inferred from early studies 
where incubation times in nude or thymectomised mice were unchanged when 
compared to wild-type (wt) mice (Mohri et al., 1987). Supporting this initial 
observation, T cell-deficient mice (e.g. CD4-/-, CD8-/-) were as susceptible to prion 
disease as wt mice (Klein et al., 1997) and T cells over-expressing PrP failed to replicate 
prions in the spleen of Prnp-/- mice (Raeber et al., 1999b), excluding them as sites for 
prion replication. Still, T cells were shown to accumulate infectivity (Raeber et al., 
1999a) and thus may contribute to the dissemination of the infectious agent in the LRS.  
B cells, in contrast, play a dominant role in neuroinvasion. B cell-deficient mice (e.g. 
RAG, µMT) do not succumb to prion disease after intraperitoneal (i.p.) inoculation with 
high doses of RML (Klein et al., 1997) and susceptibility to scrapie was restored by 
adoptive transfer with foetal liver cells (FLC) from Prnp+/+ or Prnp-/- mice, implying that 
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B cells do not support prion replication, but may instead play an indirect role by 
supporting prion-replicating cells. Interestingly, PrPSc was detected in reconstituted 
mice associated with FDCs (Klein et al., 1998). While prions are replicated in the spleen 
of transgenic mice where PrP expression was restricted to the LRS, no infectivity was 
detected in spleens of mice when PrP expression was targeted to B cells, suggesting 
that B cells alone do not suffice to support prion replication, or alternatively, that 
transport of prions to B cells may be PrP dependent (Raeber et al., 2001; Montrasio et 
al., 2001). Since B cells support the differentiation and maintenance of FDCs, the role of 
FDCs in disease pathogenesis came under scrutiny.  
The role of follicular dendritic cells  
Grafting of PrP-deficient B cells restored susceptibility to scrapie in SCID, RAG and µMT 
immunodeficient mice (Klein et al., 1998), which excludes B cells as main replication 
sites. Early evidence for the role of radiation-resistant long-lived stroma cells in prion 
pathogenesis came from studies that demonstrated that sublethal γ-irradiation of mice 
before or after peripheral inoculation with ME7 prions failed to prolong incubation 
times (Fraser and Farquhar, 1987). Likely candidates for prion replication, known to 
express high levels of PrPC are FDCs. Indeed, abnormal deposits of PrP were detected in 
association with FDCs membranes following experimental or natural TSE infection 
(Kitamoto et al., 1991; Hill et al., 1999; Jeffrey et al., 2000).  
FDCs are stroma cells in the germinal centres of lymphoid organs with long dendritic 
processes that form intricate membrane networks and are intimately associated with 
B cells. FDCs are specialized cells that capture and retain naïve antigens on their 
surfaces for long periods of time for B cell recognition (Kosco et al., 1992). The 
differentiation and maturation of FDCs and the micro-architecture of lymphoid organs 
depend on cytokines such as tumour necrosis factor (TNF) α and lymphotoxins (LT) that 
are secreted by B cells. B cell-deficient mice like SCID, RAG and µMT mice, devoid of 
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functional FDCs, are resistant to prion infection, which suggests a critical role of B cells 
in FDC maintenance. Indeed, reconstitution of these mice with replication-deficient 
stem cells restored FDC maturation and susceptibility to scrapie (Mabbott and Bruce, 
2002; Aguzzi and Heikenwalder, 2006).    
To differentiate between the role of FDC and B cells in prion pathogenesis, a series of 
seminal studies aimed to disrupt the TNF and LT signalling pathways were performed. 
The temporary depletion of FDCs by treatment with lymphotoxin-β-receptor and 
immunoglobulin fusion protein (LTβR-Ig) abolished prion infectivity in the spleen of 
mice and extended incubation periods significantly as reported in two independent 
studies using ME7 and RML prion strains (Mabbott et al., 2000; Montrasio et al., 2000). 
Similarly, knockout mice with deficient LT pathways (e.g. LTα-/-, LTβ-/- and LTβR-/- mice) 
which lack FDCs, but have functional lymphocytes, provided further evidence of a 
dominant role of FDCs in prion replication (Prinz et al., 2002). However, mice with 
disruptions in TNF signalling (e.g. TNFR1-/-) were devoid of FDCs, but almost fully 
susceptible to prions and accumulated high prion titres in lymph nodes (Prinz et al., 
2002). Furthermore, high prion titres were detected in lymph nodes of Prnp-/- mice 
reconstituted with TNFR1-/- FLCs,  suggesting that other cell types of haematopoietic 
origin might also be involved in prion replication alongside stromal FDCs (Prinz et al., 
2002; Heikenwalder et al., 2004b). Importantly, targeting of LT and TNF signalling 
pathways also severely affects the micro-architecture of the lymphoid organs with 
unknown consequences on prion propagation (Heikenwalder et al., 2004b). Effects of 
FDC abrogation were more pronounced in LT deficient than in TNF deficient mice. Of 
note, the ablation of the LT pathways also affected other cell types like DCs in the 
spleen (Wu et al., 1999) and marginal zone macrophages (Heikenwalder et al., 2004b).  
To avoid pleiotropic effects on cells other than the intended targets in knockout and 
immunodeficient mice alternative approaches using PrP-chimeric mice were pursued. 
Reconstitution of γ-irradiated wt or Prnp-/- mice with stem cells of Prnp-/- or wt mice 
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permitted to study chimeric mice where PrP expression was restricted to the stroma or 
the haematopoietic compartment, respectively (Mabbott and Bruce, 2001). Studies 
with the prion strain ME7 showed that splenic prion replication occurred only when PrP 
was expressed in the stromal compartment. No infectivity, however was detected 
when PrP expression was restricted to the haematopoietic compartment, providing 
further evidence for the involvement of FDCs in prion replication (Brown et al., 1999; 
Mohan et al., 2005). However, in similar studies using the RML strain, prions were 
replicated in both the haematopoietic and the stromal compartment provided PrP was 
expressed (Blattler et al., 1997). Furthermore, at low doses of RML both PrP-expressing 
haematopoietic and stromal cells were required for efficient replication of prions 
(Kaeser et al., 2001). Strain-dependent effects might explain the discrepancies between 
the ME7 and RML as different strains might favour different routes of neuroinvasion, 
e.g. LT-deficient mice were susceptible to Fukuoka-1 (mouse adapted CJD strain) 
challenge (Manuelidis et al., 2000). 
In summary, these studies clearly show the dominant role of FDCs in the replication 
and accumulation of prions (Brown et al., 1999; Mabbott et al., 2000; Montrasio et al., 
2000), but also present evidence of other undefined cell types that may maintain prion 
replication in the absence of FDCs (Blattler et al., 1997; Kaeser et al., 2001; Prinz et al., 
2002).  
Other cell candidates for prion replication  
Macrophages were suggested as alternative sites for prion replication and indeed 
abnormal PrP co-localised with macrophage markers in lymph nodes of TNFR1-/- and 
TNFα-/- mice (Prinz et al., 2002). Interestingly, the localisation of macrophage subsets to 
the marginal zone in lymph nodes was severely disrupted in LTβ-/- mice (refractory to 
scrapie), but not in prion-susceptible TNFR1-/- mice (Heikenwalder et al., 2004b). 
Disease-specific PrP was detected intracellularly in tingible body macrophages (TMB) of 
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germinal centres (Jeffrey et al., 2000) and in CD68 macrophages in Peyer’s patches on 
natural scrapie (Andreoletti et al., 2000). However, a direct evidence for the 
involvement of macrophages in prion replication is lacking. 
In a recent study with granulomas, a common form of chronic inflammation, 
Heikenwalder et al. showed that prions replicate in granulomas despite the lack FDCs. 
Replication was restricted to radiation-resistant stromal cells distinct from FDCs in a 
lymphotoxin-dependent manner. Fibroblastic reticular cells (FRC) and mesenchymal 
cells were identified as likely candidates of prion replication in granuloma-bearing mice 
(Heikenwalder et al., 2008). Fibroblast cell lines have been shown to replicate prions in 
vitro (Vorberg et al., 2004; Mahal et al., 2007). High PrPC expression was also detected 
in splenic capsule and trabeculae, probably from fibroblasts, the predominant cell type 
(Lotscher et al., 2003).  
Complement system 
The accumulation of infectivity and PrPSc in lymphoid organs is a hallmark of most prion 
diseases. Deposits of disease-associated PrP are detected in germinal centres 
associated to FDCs, possibly in association with immune complexes (Jeffrey et al., 
2000). FDCs are specialized antigen presenting cells that capture and retain 
unprocessed antigens for their presentation to B cells (Kosco-Vilbois et al., 1993). 
Antigens opsonised by antibody and/or complement molecules (e.g. C1q, C3) bind to 
FDC membranes via complement receptors (e.g. CD21/CD35) or Fc receptors (FcR) 
(Mabbott, 2004). The ability of FDCs to retain naïve antigens for long periods of time is 
exploited by many viruses like HIV-1 that accumulate on FDC for months to years, 
evading degradation (Smith et al., 2001). The involvement of the complement system 
in prion accumulation was demonstrated in studies that targeted various components 
of the complement system. Depletion of C1q, C3 or the receptor CD21/CD35, but not 
FcR, prolonged incubation times and impaired prion accumulation in spleen (Klein et 
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al., 2001; Mabbott et al., 2001; Zabel et al., 2007). Binding of antibodies and/or 
complement factors target antigens not only to FDCs but also to other cell types 
expressing CD21/CD35 such as B cells, dendritic cells and macrophages. C1q was shown 
to participate in PrPSc endocytosis by DCs (Flores-Langarica et al., 2009). Adoptive 
transfer experiments where CD21/CD35 expression was restricted to stromal or 
haematopoietic cells demonstrated that its expression in both compartments is 
required for efficient prion propagation although longer incubation times were 
observed when CD21/35 expression was restricted to the stromal compartment (Zabel 
et al., 2007).   
1.3.3 Transport of prions to the LRS and the CNS 
Following peripheral inoculation, prions are transported to lymphoid organs where 
they replicate and accumulate long before they are detected in the brain (Eklund et al., 
1967). While most research focused on the identification of cell types that support 
prion replication in the LRS, the molecular mechanisms that lead to prion dissemination 
remain largely unknown. Circulating haematopoietic cells like lymphocytes, 
macrophages and DCs are plausible candidates for the transport of prions from initial 
sites of infection to their replication sites. The molecular link of prion dissemination 
from immobile FDCs, widely recognized as the major sites of prion replication (Mabbott 
and Bruce, 2002) to the brain via peripheral nerves remains unclear.  
Upon oral challenge, prions are detected in the gut-associated lymphoid tissue, mainly 
in Peyer’s patches, before they are found in lymph nodes and spleen (Kimberlin and 
Walker, 1989a). Transport of prions across the intestinal epithelium is thought to be 
mediated by microfold (M) cells, specialised epithelial cells that sample and deliver 
antigens from the gut lumen to immune cells in Peyer’s patches (Heppner et al., 2001). 
After crossing the epithelium, lymphocytes, macrophages and DCs could be involved in 
the transport of prions to their sites of replication in Peyer’s patches and mediate the 
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transport to other organs via the lymphatics or the blood to the spleen (Huang and 
MacPherson, 2004; Defaweux et al., 2005).  
Lymphocytes 
Targeted defects in T cell subsets did not affect incubation times indicating that T cells 
are dispensable for lymphoinvasion (Klein et al., 1997; Raeber et al., 1999b). The 
prevention of clinical disease in B cell-deficient mice after i.p. inoculation with prions 
highlights the critical role of B cells in prion propagation (Klein et al., 1997; Klein et al., 
1998). It was suggested that B cells play an indirect role in the disease process by 
supporting the maturation of stromal cells by LT signalling. While B-cell deficient mice 
were entirely resistant to peripheral inoculation with prions, FDC-deficient mice were 
only partially resistant (Heikenwalder et al., 2004b). However, since splenic B cells and 
T cells isolated from scrapie infected mice were infectious both could contribute to 
prion dissemination within the lymphoid organs (Raeber et al., 1999a). Due to their 
close contact to FDCs circulating B cells were suggested to constitute the link between 
infected FDCs and nerve endings. However depletion of germinal centre B cells by 
interference of CD40 signalling did not affect pathogenesis (Heikenwalder et al., 2007).  
Macrophages and dendritic cells 
Because of their migratory properties and their role as antigen presenting cells, 
macrophages and DCs were suggested as candidates for the dissemination of prions. 
Both, enriched fractions of macrophages (Kuroda et al., 1983; Carp et al., 1994) and 
highly purified DCs are infectious and retain more infectivity than lymphocytes 
(Aucouturier et al., 2001). The rapid uptake and degradation of PrPSc was demonstrated 
in vitro for DCs and macrophages (Rybner-Barnier et al., 2006). In Peyer’s patches PrPSc 
is first found in CD68+ cells, i.e. macrophages and some DCs, before it was detectable 
on FDCs (Andreoletti et al., 2000; Huang and MacPherson, 2004). Abnormal PrP 
deposits were also detected in tingible body macrophages of germinal centres (Jeffrey 
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et al., 2000). Macrophages might contribute to prion propagation (Prinz et al., 2002), 
but might also be involved in the clearance of prions as suggested by in vitro 
experiments that showed a reduction of infectivity in the presence of macrophages 
(Carp and Callahan, 1982; Rubenstein et al., 1984; Beringue et al., 2000). A series of in-
vivo treatments known to interfere with the normal macrophage status failed to affect 
disease progression (reviewed in Beringue et al., 2002). The activation of Toll-like 
receptors (innate immune receptors) has a protective effect to prion diseases (Sethi et 
al., 2002). Treatment with clodronate, known to deplete macrophages in vivo resulted 
in a significant increase of PrPSc in the spleen (Beringue et al., 2000) and Peyer’s 
patches (Maignien et al., 2005) at early stages, suggesting a protective role of 
macrophages. This treatment, however, also affects FDCs and B cells and could 
therefore have an impact on PrPSc levels (Beringue et al., 2000).   
DCs are migratory cells involved in antigen sampling and presentation to T cells in the 
lymphoid organs. Contrary to macrophages, some subsets of DCs have been shown to 
retain native antigen for long periods of time, making them ideal candidates for a role 
in prion dissemination (Banchereau et al., 2000). Indeed, DCs, but not lymphocytes, 
isolated from lymph by thoracic duct cannulation acquired PrPSc following oral 
inoculation, yet no infectivity was detected in these cells (Huang et al., 2002). The close 
contact between DCs and nerve endings in T cell areas of lymphoid organs suggests a 
role of DCs in neuroinvasion, although intervention studies to verify this hypothesis are 
pending. Intravenous inoculation of infectious and viable DCs restored prion 
susceptibility of Rag-1-/- mice, suggesting the DCs might suffice to propagate prions 
from the periphery to the CNS (Aucouturier et al., 2001). These results however, were 
not confirmed by other experiments (Rybner-Barnier et al., 2006; Raymond and 
Mabbott, 2007). Differences in the lymphoid microarchitecture between different 
mouse models that result in a higher innervation of Rag-1-/- mice as compared to 
TNFR1-/- may explain differences in the transfer rates of prions (Raymond and Mabbott, 
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2007). The role of DCs in prion dissemination was investigated in several depletion 
studies. However, the rapid replenishment of DCs from precursors was not well 
controlled in these studies, and therefore the conclusions are dubious. While 
disruption of lymphoid DCs (DEC205+ CD11c+) did not affect disease onset following 
intraperitoneal or oral inoculation (Oldstone et al., 2002), longer incubation times were 
observed in mice defective for lymphoid DCs (CD8+ CD11c+) after i.p., but not oral 
inoculation (Sethi et al., 2007). Temporal depletion of migratory DCs delayed disease 
onset and resulted in reduced infectious titres in Peyer’s patches, mesenteric lymph 
nodes (MLN) and the spleen after oral inoculation (Raymond et al., 2007). In a similar 
study reduced levels of PrPSc were found in the spleen and brain, and incubation times 
were prolonged as compared to controls following i.p., but not oral inoculation 
(Cordier-Dirikoc and Chabry, 2008). The disruption of DC migration by targeted 
disrupton of chemokine CCL19/CCL21 release, required for homing to T cell zones did 
not affect prion pathogenesis (Levavasseur et al., 2007). In summary, to date no clear 
evidence for a role of DCs in prion dissemination has been provided. 
1.3.4 Neuroinvasion 
From their sites of replication in the LRS, prions are thought to be transported to the 
CNS via the autonomic nervous system. Abnormal PrP was detected along the spinal 
cord and peripheral nerves (Kimberlin and Walker, 1980; McBride and Beekes, 1999). In 
particular, prions seem to gain access to the nervous system via sympathetic nerves 
that innervate the lymphoid organs as demonstrated by the fact that incubation times 
were shortened by impairment of the sympathetic nervous system and prolonged by 
sympathetic hyperinnervation (Glatzel et al., 2001). Alternative routes for 
neuroinvasion through parasympathetic nerves (e.g. vagus nerve) have been proposed 
(Baldauf et al., 1997; McBride et al., 2001). Neuroinvasion is accelerated in mouse 
models where the distance between FDCs and nerve endings is reduced (Prinz et al., 
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2003), but the mechanisms by which prions gain access to peripheral nerves are not 
well understood. Nerve endings are rarely found in B cell follicles, where FDCs are 
located, but instead in T cell areas. Interactions between DCs and nerve fibres were 
observed by confocal microscopy in scrapie infected lymphoid organs (Dorban et al., 
2007).  
Irrespective of the routes by which prions reach the CNS, the expression of PrPC is 
required for neuroinvasion. The requisite of PrPC expression for neuroinvasion and 
prion dissemination is evident from several experiment paradigms. Adoptive transfer of 
bone marrow from wt mice to Prnp-/- mice reconstituted the capability of the spleen to 
accumulate prions but not neuroinvasion (Blattler et al., 1997; Kaeser et al., 2001). 
Furthermore, no prion pathology was observed in Prnp+/+ neurografts introduced into 
Prnp-/- mice after peripheral infection (Blattler et al., 1997), but after intracerebral 
inoculation (Brandner et al., 1996a). Taken together these data indicate that PrPC 
expression is crucial for prion transport to the CNS and within the CNS.  
1.4 Mechanisms for the lateral spread of prions 
The cellular mechanisms underlying the transfer of prions between cells in vivo are 
unknown and may involve close contacts between membranes (Baron et al., 2006). 
Several routes for transmission of prions have been proposed, including direct cell-to-
cell contact (Kanu et al., 2002), transmission of prions via membrane nanotubes 
(Gousset et al., 2009) and the release of prions via exosomes (Fevrier et al., 2004) 
(figure 1.4).  
The detection of newly infected cells in co-cultures of infected and uninfected cells 
showed that prions are preferentially transferred to neighbouring cells, although long-
range intercellular transfer cannot be excluded (Paquet et al., 2007). The transfer of 
infectivity by direct cell-to-cell contact was shown in vitro by co-culture of fixed prion-
infected cells with uninfected cells (Kanu et al., 2002). The mechanisms involved in the 
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cell-to-cell transfer of prions are unknown, but may involve panning of PrPSc as 
documented for GPI-proteins (Medof et al., 1996; Liu et al., 2002), or trans conversion 
of PrPC into PrPSc by PrPSc on the adjacent cell (Kanu et al., 2002; Hooper, 2002). 
Although a transfer of prions between fixed prion-infected cells and uninfected cells 
was observed, the efficiency of this transfer was much higher in viable infected cells, 
implying that active biological processes may be involved in the transfer of infectivity 
(Kanu et al., 2002). Although co-cultures of infected and uninfected cells that are 
separated by a porous membrane are frequently used to address prion release into the 
extracellular medium the possibility of a focal release of infectivity at sites of close 
juxtaposition between cells cannot be excluded (Ashok and Hegde, 2006). Several 
neuronal cell lines secrete infectivity into the culture medium and conditioned media 
from prion-infected cells can be used to initiate infection (Schatzl et al., 1997; Baron et 
al., 2006). Membranous channels, known as tunnelling nanotubes (TNT) that connect 
different cell types were recently suggested as a route for the intercellular transfer of 
prions where fluorescent-tagged PrP was shown to travel along nanotubes between 
cells (Gousset et al., 2009).  
The role of exosomes in the spread of prions 
During endocytic trafficking proteins from the plasma membrane are internalized and 
recycled back to the membrane or sorted into late endosomes and lysosomes for 
degradation. Exosomes are small vesicles (30-100 nm) of endosomal origin that are 
formed by inward budding of the late endosome membrane into maturing 
multivesicular bodies (MVB). Mature MVBs either fuse with lysosomes to deliver their 
cargo for degradation, or fuse with the plasma membrane to release exosomes into the 
extracellular medium. Once released, exosomes could be endocytosed by neighbouring 
cells (Thery et al., 2002). Endosomes, lysosomes and exosomes were shown to 
accumulate PrPSc (McKinley et al., 1991; Arnold et al., 1995; Fevrier et al., 2004).  
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Secreted by a variety of cells including reticulocytes, mast cells, DCs, lymphocytes and 
macrophages, as well as a number of immortalized cell lines (Johnstone et al., 1987; 
Stoorvogel et al., 2002; Thery et al., 2002; Couzin, 2005; van Niel et al., 2006), 
exosomes could enable the transfer of prions between cells without the requirement of 
direct cell-to-cell contact (Vella et al., 2008b). Exosomes are found in body fluids in vivo 
(Pisitkun et al., 2004; Caby et al., 2005; Knepper and Pisitkun, 2007; Vella et al., 2008a) 
and in germinal centres, associated to FDCs (Denzer et al., 2000). Similarly, extracellular 
deposits of disease-associated PrP were shown in proximity to FDC surfaces (Jeffrey et 
al., 2000). Interestingly, exosomes on the surface of FDCs are not released by FDCs 
themselves but by other cell types, most likely B cells (Denzer et al., 2000). However, 
no evidence for the presence of disease-specific PrP in exosomes attached to FDCs was 
found (McGovern and Jeffrey, 2007). In vitro studies showed that B cell-derived 
exosomes bind to extracellular matrix (ECM) proteins (collagen I and fibronectin) and 
activated fibroblasts (Clayton et al., 2004).  
Purified exosomes from infected cell lines are PrPSc positive and infectious (Fevrier et 
al., 2004; Vella et al., 2007; Alais et al., 2008). Furthermore, transfer of infectivity was 
shown to occur between neuronal and non-neuronal cell lines (Vella et al., 2007). 
Retroviruses including HIV-1 and murine leukaemia virus (MuLV) have been shown to 
use the endosomal route of cells to bud out of infected cells. Interestingly, retroviral 
infection strongly enhances the release of infectivity (Leblanc et al., 2006). Despite 
several in-vitro studies that support the role of exosomes in the spread of infectivity, in 
vivo evidence is missing. 
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Figure 1.4 Mechanisms for the lateral spread of prions. (A) Two mechanisms for the transfer of 
infectivity by direct cell-to-cell contact were suggested. PrPSc on one membrane could promote the 
conversion of PrPC on the adjacent membrane. Alternatively, as documented for GPI-anchored proteins, 
PrPSc could jump and be inserted into the contiguous membrane. (B) Exosomes, vesicles of endocytic 
origin, formed by invagination of the MVB membrane, are released into the extracellular medium by 
fusion of MVBs with the plasma membrane. Exosomes could be endocytosed by the neighbouring cell 
and deliver their cargo. (C) Nanotubes, membranous bridges between different cell types were 
suggested to mediate the transfer of PrPSc between cells by active vesicle transport. Reproduced from (A) 
Curr. Biol., Hooper N. M., 2002, Vol. 12, pp R248-R249 (Hooper, 2002) (B) Annu. Rev. Biochem., Caughey et al., 2009, 
Vol. 78, pp 177-204 (Caughey et al., 2009) (C) Nat. Cell. Biol., Gerdes H. H., 2009, Vol 11, pp 235-236 (Gerdes, 2009). 
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1.5 Aims of the thesis 
To establish a standardised and statistically robust infectivity assay 
A reliable determination of prion titres is fundamental to study prion diseases where 
differences in titres may be critical to assess the efficacy of therapeutic interventions. 
Where the size of experimental groups in bioassays is greatly restricted by ethical and 
economical factors, resulting in underpowered studies, in-vitro determination of prion 
titres may overcome these limitations by extending the experimental scope. We 
therefore aim to establish a standardised and statistically robust method for titre 
determination of tissue and cell homogenates. 
To determine the kinetics of prion accumulation in splenic cell types 
Studies with immuno-deficient and knockout mice showed that both haematopoietic 
and stromal cells play fundamental roles in prion pathogenesis (Blattler et al., 1997; 
Kaeser et al., 2001). Comprehensive studies to determine the infectious state of 
candidate cell types during early stages of pathogenesis have not been performed to 
date due to the prohibitively large number of animals required for in-vivo infectivity 
testing. By taking advantage of fast in-vitro titre determination (SCA) and high-capacity 
cell sorting we aim to establish a procedure to determine the infectious titres of various 
splenic cell types including B and T cells, DCs, the DC subset plasmacytoid DCs (pDC), 
macrophages and natural killer (NK) cells at early stages of prion pathogenesis. 
To determine prion titres of stromal cell types 
FDCs were shown to accumulate disease-specific PrP (Jeffrey et al., 2000; Sigurdson et 
al., 2002) and are considered prime candidates for prion replication in the LRS 
(Mabbott and Bruce, 2002). However, to date no study reported prion titres of FDCs. 
We therefore aim to establish a method to isolate FDCs by immuno-affinity separation 
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and to determine their infectious state. Evidence of prion replication in the absence of 
FDCs suggests that other stromal cells are replication-competent (Prinz et al., 2002). 
For instance, mesenchymal or fibroblastic reticular cells were proposed to replicate 
prions in granulomas-bearing mice (Heikenwalder et al., 2008) and several fibroblasts 
lines have been shown to replicate prions in vitro (Vorberg et al., 2004). We therefore 
aim to establish splenic stromal cell culture models from scrapie-infected mice to 
confirm that stromal cell types are permissive to prions and to study prion propagation 
ex vivo. 
To investigate the role of exosomes for the spread of prions 
A potential role of exosomes for the intercellular transmission of prions was deducted 
from in-vitro studies with immortalised cell lines. In these studies secreted exosomes 
were purified from culture supernatants and were shown to be PrPSc positive and 
infectious (Fevrier et al., 2004; Vella et al., 2007; Alais et al., 2008). Exosomes are found 
in vivo in body fluids (Pisitkun et al., 2004; Caby et al., 2005) and in germinal centres of 
lymphoid organs associated to FDCs (Denzer et al., 2000), but their role in prion 
dissemination in the LRS remains unknown. Furthermore, all major immune cells 
including DCs, B cells, T cells and macrophages secrete exosomes (Thery et al., 2002). 
We will therefore investigate whether infectious exosomes are secreted from splenic 
cells of scrapie infected mice ex vivo. 
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MATERIALS AND METHODS 
2.1 Isolation of cell fractions from spleen tissue 
2.1.1 Isolation of splenocytes 
Splenocytes were isolated by enzymatic digestion from freshly dissected spleens. To 
maximise the release of non-haematopoietic stromal cells and other resident cells that 
are strongly attached to connective tissue, spleens were digested in successive cycles 
as described previously by Kosko et al. with minor modifications (Kosco et al., 1992). 
Briefly, spleens were cut into small pieces and incubated at 37 °C with an enzyme 
cocktail, containing 2.5 mg/ml collagenase IV (Worthington Biochemical Corp., 
Lakewook, NJ), 0.05 % dispase 2 (Sigma-Aldrich, Dorset, UK) and 1 mg/ml DNase I 
(Roche Diagnostics Ltd, West Sussex, UK) in Iscove's Modified Dulbecco's Media 
(IMDM) (Invitrogen, Paisley, UK). After 15-20 min, partially digested tissue was gently 
dispersed with a serological pipette and released cells were transferred into a tube on 
ice. Fresh enzyme cocktail was added to the remaining tissue fragments and digested 
for another three cycles. Pooled cells were then passed through a 70 μm nylon mesh 
and pelleted at 300 x g for 10 min. To remove erythrocytes, splenocytes were 
resuspended in 10 ml erythrocyte lysis buffer [155 mM NH4Cl, 10 mM KHCO3, 0.1 mM 
Ethylene-diamine-tetra-acetic acid (EDTA), pH 7.0] and incubated at room temperature 
for no more than 1 min. After adding 40 ml IMDM medium to stop lysis, cells were 
pelleted at 300 x g for 10 min. Splenocytes were then layered onto Lympholyte M 
(Cedarlane Laboratories, Hornby, Ontario, Canada) gradients and centrifuged at 
1500 x g for 20 min to remove dead cells and debris essentially as described by the 
manufacturer. Purified splenocytes were washed in IMDM supplemented with 10 % 
heat inactivated foetal calf serum (FCS), 100 U/ml Pen-strep, 2 mM L-glutamine and 
50 μM 2-mercaptoethanol (complete IMDM) and centrifuged for 10 min at 800 x g. 
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Cells were resuspended in chilled MACS buffer [0.5 % bovine serum albumin (BSA) and 
2 mM EDTA in phosphate-buffered saline (PBS)] and the number of splenocytes was 
determined using a Coulter counter Z2 (Beckman Coulter, High Wycombe, UK) at an 
upper threshold of 15 μm and a lower threshold of 5 μm. 
2.1.2 Isolation of splenic cell types by magnetic-activated cell sorting 
Specific cell populations were enriched from total splenocytes by sequential magnetic-
activated cell sorting (MACS) using antibody-coated magnetic microbeads (Miltenyi 
Biotech Ltd, Surrey, UK) as depicted in figure 2.1. To block unwanted binding of 
antibodies to cells expressing Fc receptors (FcR), splenocytes were suspended at a 
concentration 2 x 108 cells/ml MACS buffer and incubated with 25 μl FcR blocking 
reagent (Miltenyi Biotech Ltd, Surrey, UK) per 108 cells. Cells were magnetically 
labelled, essentially as specified by the manufacturer (Miltenyi Biotech Ltd, Surrey, UK) 
using the following microbeads: CD11c for dendritic cells (DC), mPDCA-1 for 
plasmacytoid DCs (pDC), CD11b for myeloid cells, CD49b for natural killer (NK) cells and 
NK-T cells, CD19 for B cells and CD90 for T cells. Since CD11b antigens are expressed on 
both macrophages (CD11c- CD11b+) and mDCs (CD11c+ CD11b+), we did two positive 
rounds of selection with CD11c microbeads before isolating CD11b+ macrophages. 
Macrophages were purified by fluorescence-activated cell sorting (FACS) using a MoFlo 
cell sorter (Dako, Cambridgeshire, UK). Briefly, MACS-isolated CD11b+ cells were 
incubated for 30 min on ice with FITC-conjugated anti-CD11c (clone HL3, 1:100) and PE-
conjugated anti-CD11b (clone M1/70, 1:50) (BD Biosciences, Oxford, UK) and CD11c-
 CD11b+ cells were sorted at a concentration of 5-10 x 106 cells per ml. Isolated cells 
were counted with a Coulter Counter (Beckman Coulter, High Wycombe, UK) and 
stored at -80 °C until further processing.  
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Figure 2.1 Standard isolation procedures of splenic cells by MACS. Splenocytes were released by 
repeated collagenase digestion, followed by removal of red blood cells and purification splenocytes on 
lympholyte gradients. Specific cell types were isolated by MACS using microbeads (Miltenyi Biotech Ltd, 
Surrey, UK) as indicated. Alternatively, macrophages were purified by FACS as CD11c- CD11b+ cells. 
 
Isolation of plasmacytoid dendritic cells and lymphocytes from blood 
Whole blood was obtained from euthanized mice by cardiac puncture and collected in 
4 mM EDTA used as anticoagulant. Blood samples were further diluted into MACS 
buffer, layered onto Lympholyte M and centrifuged for 20 min at 1500 x g at 22 °C. 
Cells from the interface were collected and erythrocytes removed as described before. 
After washing, blood cells were resuspended in MACS buffer and pDCs and 
lymphocytes were isolated by MACS as described above.  
2.1.3 Isolation of follicular dendritic cell clusters 
Follicular dendritic cell (FDC) clusters were separated by four successive 
sedimentations at unit gravity as previously described (Wekerle et al., 1980; Tsunoda et 
al., 1990). Before the enzymatic digestion of spleen tissue, the majority of lymphocytes 
were eliminated by flushing spleens repeatedly with IMDM 10 % FCS medium. The 
remaining tissue was minced and digested as described above. Pooled cells were 
pelleted at 200 x g for 5 min, resuspended in MACS buffer and subjected to 1 x g 
sedimentation in FCS for 20 min on ice. Cells from the serum layer were collected and 
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washed in MACS buffer. Pellets were resuspended in MACS buffer and layered onto FCS 
for three further sedimentation cycles (figure 2.2). To remove macrophages and 
fibroblasts, cell clusters were cultured for 30 min in tissue culture dishes at 37 °C and 
5 % CO2. Non-adherent FDC clusters were collected and counted in a Coulter counter at 
an upper threshold of 39 μm and a lower threshold of 19 μm. 
 
 
Figure 2.2 Purification of follicular dendritic cell clusters by a four step 1 x g sedimentation procedure. 
FDC/B cell clusters sediment at a faster rate than single cells and were recovered in the lower fraction of 
the gradients. Recovered cell clusters were incubated on plastic dishes for 30 min to allow adherence of 
macrophages, fibroblasts. Non-adherent cells containing mainly FDC clusters were collected.  
 
2.2 Cell culture 
All tissue culture work was performed in a class II or laminar flow tissue culture hood, 
using sterile techniques. All cell culture incubations were carried out at 37 °C in a 
humidified 5 % CO2 atmosphere.  
2.2.1 Short-term primary cultures of splenic cells 
B cells, T cells and DCs were isolated by MACS and cultured at a concentration of 
1-4 x 106 cells/ml in complete IMDM medium. To remove exosomes from serum, heat 
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inactivated FCS was spun at 100,000 x g for 2 h in an Optima XL-100K Beckman 
ultracentrifuge with a rotor SW70 before use. Freshly isolated splenic cells were 
stimulated with LPS (1 μg/ml, Sigma-Aldrich, Dorset, UK), IL-4 (10 ng/ml, AbD Serotec, 
Kidlington, UK) and GM-CSF (200 U/ml, gift from Dr Pichlmaier). Cells were cultured in 
complete IMDM medium at 37 °C and atmospheric CO2 undergo rapid necrosis and 
were used as passive leakage controls. After 38 h in culture, supernatants from 
different cell types at various culture conditions were harvested for the isolation of 
exosomes. The viability of the cells was assessed using 7-Aminoactinomycin D (7-AAD) 
exclusion (BD Biosciences, Oxford, UK).  
2.2.2 Long-term stroma cell cultures 
Following enzymatic digestion of spleens, released cells were counted and separated 
by density gradient centrifugation. Two-layer Percoll (GE Healthcare, Buckinghamshire, 
UK) gradients were prepared by layering 4 ml of a 18 % Percoll solution (1.03 g/ml) over 
6 ml of a 56 % Percoll (1.08 g/ml) diluted in 0.15 M NaCl. Aliquots of 500 μl containing 
2 x 108 cells were loaded per gradient and centrifuged at 8500 x g (Beckman 
ultracentrifuge, rotor 70.1 Ti) for 40 min at 22 °C. Low density cells as indicated in 
figure 2.3 were collected in complete IMDM medium and centrifuged at 800 x g to 
remove Percoll.  
Cells were cultured at a concentration of 1-4 Mio/ml complete IMDM. After 24 h, non-
adherent cells were removed and fresh medium was added to the cultures. Cells were 
passaged twice weekly. 
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Figure 2.3 Separation of low density cells using a Percoll gradient. About 2 x 108 collagenase released 
splenic cells were loaded per gradient and spun at  8500 x g for 40 min at 22 °C with no brake. 
Lymphocytes and red blood cells (RBC) are readily separated accordingly to their buoyant densities. 
 
2.2.3 Culture and maintenance of neuroblastoma N2a cells 
Highly prion-susceptible neuroblastoma cells, subclone N2aPK1-2 cells were used for 
infectivity assays. Cells were cultured in OptiMEM (Invitrogen, Paisley, UK), 
supplemented with 10 % γ-irradiated FCS (Invitrogen, Paisley, UK) and 1 % Pen-step 
(Invitrogen, Paisley, UK) (OFCS). Since prolonged cell passages are known to affect 
prion susceptibility of cells (Klohn et al., 2003), all experiments were performed with 
freshly thawed cells. PK1-2 cells were quickly thawed in a 37 °C water bath and pre-
warmed growth medium was added slowly at 5 min intervals. Cells were then 
centrifuged at 300 x g for 4 min, resuspended in 1 ml medium and transferred to a 
10 cm tissue culture plate (VWR, West Sussex, UK). Growth medium was regularly 
changed and cells were split 1:10 (1:8) into 15 cm plates (VWR, West Sussex, UK) every 
3-4 days. 
2.3 Isolation of exosome-enriched membrane fractions and analysis by 
electron microscopy 
Exosomes were isolated by differential centrifugation as previously described 
(Johnstone et al., 1987; Thery et al., 1999; Wolfers et al., 2001). Briefly, supernatants 
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from cell cultures of splenic cell types were retrieved after 38 h, sequentially 
centrifuged at 300 x g for 10 min and 5000 x g for 20 min and ultracentrifuged at 
10,000 x g for 30 min and 100,000 x g for 2 h with a SW70 rotor (Beckman Coulter, High 
Wycombe, UK)as shown in figure 2.4. The pellet was resuspended in PBS and used 
immediately or stored at -70 °C until further use.  
For analysis by electron microscopy 3 μl aliquots of 1:10 diluted resuspended pellets 
were adsorbed onto glow-discharged carbon-coated grids and negatively stained with 
1 % uranyl acetate. Grids were examined by electron microscopy at the Bloomsbury 
Centre for Structural Biology (Birkbeck College, London, UK) by Dr Howard Tattum 
(MRC Prion Unit, London, UK). To determine the number of exosome-like membrane 
particles 20 random images taken at a magnification of x 10,000 were recorded per 
condition and the number of particles was counted in a blinded manner. 
 
 
Figure 2.4 Isolation of exosomes from primary cultures of splenic cells. After 30 h culture of splenic 
cells, conditioned medium was collected and serially centrifuged to remove cell and debris. Exosomes 
were pelleted at 100,000 x g for 2 h.  Adapted from Brain Res. Rev., Agnati et al., 2010, Vol. 64, pp 137-159 
(Agnati et al., 2010). 
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2.4 Protein determination 
Where cell counts could not be accurately determined (e.g. FDC clusters, stroma cells) 
infectious titres were expressed per μg protein. For this purpose, cell aliquots were 
spun at high speed and pellets stored at -70 °C. Pellets were resuspended in 100-200 μl 
lysis buffer (150 mM NaCl, 0.1 % Triton, 0.1 % sodium deoxycholate) for 15 min on ice. 
Total protein concentration was determined by Bio-Rad Bradford assay. Cell lysates 
were spun at high speed for 1 min and diluted 1:10 or 1:20 in PBS before loading 25 μl 
per well of a 96-well plate.  Protein standards from 0 to 500 μg were prepared fresh 
from a BSA standard (Thermo Fischer Scientific, West Sussex, UK). BSA standard and 
samples were transferred in triplicates into plates before adding 200 μl of diluted dye 
reagent (Bio-Rad, Bath, UK) according to manufacturer instructions. Absorbance was 
measured at 595 nm on a Tecan plate reader (Sunrise, Reading, UK). Protein 
concentrations were determined in the linear range of standard dilution series.  
2.5 In vivo depletion of plasmacytoid dendritic cells and RML inoculation 
PDCs were depleted in vivo as previously described (Bailey-Bucktrout et al., 2008). Four 
mice were injected i.p. with 250 μg of anti-mPDCA-1 antibody (Miltenyi Biotech Ltd, 
Surrey, UK) every 2-3 days for a total number of eight injections. Four control mice 
received the same amount of purified rat IgG2b (eBioscience, Hatfield, UK) as isotype-
matched control antibody. One day after the second injection of antibodies, mice were 
inoculated i.p. with a 1 % dilution of RML I6200 (see next section). Animals were culled 
at 19 dpi and spleens and mesenteric lymph nodes were collected for titre 
determination. 
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2.6 Infectivity measurements 
2.6.1 Animals and scrapie inoculation 
RML prion-infected brain homogenate (I6200) [10 % (w/v)] and normal CD1 brain 
homogenate (I8402) [10 % (w/v)] were prepared as previously described (Cronier et al., 
2008). After thawing, aliquots of RML or normal brain homogenates [10 % (w/v)] were 
ribolyzed or passed through needles with increasing gauge to break up any particulate 
matter before dilution into 1 % normal CD1 brain homogenate.  
Six to eight week old female 129/Sv x C57BL/6 mice were purchased from Harlan Ltd., 
Oxfordshire, UK). Prnp-/- mice used here were derived from the original Zurich I mice 
(Bueler et al., 1992) and crossed onto the FVB/N background for 10 generations (Isaacs 
et al., 2008). Mice were inoculated intraperitoneally (i.p.) with 100 μl of 1 % RML or 1 % 
uninfected CD1 brain homogenate and culled at early stages of prion disease prior to 
the manifestation of neurological symptoms. Where prion titres were determined by 
bioassay, mice were inoculated intracerebrally (i.c.) with 30 μl inoculum and the 
incubation time until manifestation of neurological signs of scrapie was recorded. All 
mice were observed daily for indications of ill-health. All experimental procedures were 
conducted in compliance with Home Office regulation. 
2.6.2 Preparation of samples for infectivity testing 
Preparation of the RML standards 
RML standards for infectivity assays were prepared by serial 10-fold dilutions (from 10-2 
to 10-9) of 10 % RML homogenate into 10 % normal CD1 brain and further diluted 1:10 
in 1 % normal CD1 for tg20 inoculation or 1:1000 in OFCS for the infection of cells. 
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Preparation of tissue homogenates and cell homogenates  
To determine infectious titres of tissue samples, spleens and mesenteric lymph nodes 
from scrapie-infected and control mice were minced and transferred into 2 ml 
microtubes (Sarstedt Ltd., Leicester, UK) containing zirconium beads. Ten percent 
homogenates (w/v) were prepared in PBS-buffered sucrose (0.32 M) in presence of 1× 
dilution of Protease Inhibitor Cocktail Set I (100×, Pierce, Leicestershire, UK) and 
25-50 U benzonase (Novagen, Madison, WI) using a Ribolyser (Hybaid, Cambridge, UK) 
at maximum speed for two cycles of 45 s. Homogenates were cooled on ice between 
homogenisation rounds and before serial dilutions. 
Aliquots of MACS-isolated splenic cells were ribolyzed at a concentration of typically 
2 × 107 cells/ml complete medium, supplemented with protease inhibitors as described 
before. All homogenates were kept on ice until further processing. Where sonication 
was used to homogenise the cells, aliquots of MACS-isolated cells were transferred into 
0.2 ml Thermo tubes (Thermo Fischer Scientific, West Sussex, UK) and placed beneath 
the sonication probe in ice water. Cells were homogenised in five cycles of 30 s at 30 % 
power using a Status 200 sonicator (Philip Harris Scientific, Hyde, UK). Neat 
homogenates were cooled on ice and serially diluted in OFCS or 1 % uninfected CD-1 
brain for the determination of infectivity by in-vitro testing or the mouse bioassay, 
respectively. Dilutions were done in a way that the 10-1 dilution corresponded to 
2 × 106 cell equivalent/ml, that is 6 × 105 cells in 300 μl per well of a 96-well plate or 
6 × 104 cells in 30 μl inoculated i.c. in tg20 mice. Where aliquots < 107 cells were 
ribolyzed uninfected splenocytes (5 × 106 cells/ml in OFCS) were added to avoid loss by 
binding to plastic surfaces.  
Infectivity of exosome pellets 
Exosome pellets obtained by high speed centrifugation of conditioned medium were 
resuspended in 500 μl OFCS and serially diluted in OFCS for infectivity determination. 
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Prion titres were referred to the initial number of cells that formed the cell cultures and 
expressed per 106 cell equivalent.  
2.6.3 Infectivity assays  
Scrapie Cell Assay in End Point format 
Infectious titres were determined by the Scrapie Cell Assay in End Point format (SCEPA) 
as described previously (Klohn et al., 2003; Mahal et al., 2008) with minor 
modifications. Briefly, 2 × 104 PK1-2 cells in OFCS were plated into wells of 96-well 
plates. After 16 h cells were incubated with 300 μl aliquots of serially diluted 
homogenates. Three days later cells were initially split twice 1:2 and once 1:3 every 
other day. Prior to resuspending cells, half the medium was replaced with fresh OFCS 
for all previous cell passages. After three days cells were split 1:6 every 3-4 d. Aliquots 
of 25,000 cells were transferred onto Elispot plates after the sixth and seventh split 
(MultiScreen HTS-IP Filter Plate, Millipore, Watford, UK) and dried at 50 °C for at least 
1 h. PrPSc-positive cells were detected by enzyme-linked immunosorbent assay (ELISA). 
Briefly, plates were incubated with Proteinase K (PK) (Roche Diagnostics Limited, West 
Sussex, UK) 1:10,000 in lysis buffer (50 mM Tris.HCl, pH 8.0, 150 mM NaCl, 0.5 % 
Na deoxycholate, 0.5 % Triton-X) for 1 h at 37 °C. After inactivating PK with 1 mM 
phenylmethylsulfonyl fluoride (PMSF) for 10 min, samples were denatured with 3 M 
guanadinium thiocyanate in 1 M Tris.HCl (pH 8.0) for 10 min and washed excessively, 
incubated with superblock (Pierce) and labeled with 0.6 μg/ml of anti-PrP antibody 
ICSM18 in TBST (10 mM Tris.HCl, pH 8.0, 150 mM NaCl, 0.1 % Tween-20) and 1 % milk 
powder. After 1 h plates were washed 5 times with TBST and incubated with alkaline 
phosphatase (AP) conjugated anti-IgG1 (Southern Biotech, Cambridge, UK) 1:6000 in 
TBST/1 % milk for another hour. After washing with TBST, plates were incubated with 
AP substrate (Bio-Rad, Bath, UK) for 30-40 min. Plates were then washed twice with 
dH2O, air-dried and stored at -20 °C. PrPSc positive cells were counted using a Zeiss KS 
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ELISPOT system (Stemi 2000-C stereo microscope equipped with a Hitachi HV-C20A 
color camera and a KL 1500 CD scanner and WellScan software from Imaging 
Associates). Using the training feature of the WellScan software, the detection of PrPSc-
positive cells was optimised to yield maximal signal-to-noise ratios.  
Bioassay with Tg20 indicator mice 
To determine prion titres by bioassays, groups of 6 Tg20 mice (Fischer et al., 1996) 
were inoculated i.c. with 30 μl of serial dilutions of cell homogenates (pDCs and B cells) 
and RML brain homogenates.  
Calculation of infectious titres  
The ratio of PrPSc-negative wells per dilution was determined. Wells were scored 
positive if the spot number exceeded the background level, defined as the mean spot 
number in control (uninfected) wells plus 6 times the standard deviation. Infectious 
titres were estimated by statistical modelling using generalized linear models in 
cooperation with the Dept. Statistical Science, UCL. For comparative purposes, the 
effective median dose, dilution leading to 50 % scrapie sick mice or PrPSc-positive wells, 
and standard errors were determined by the Spearman-Karber formula (Dougherty, 
1964). 
2.6.4 Detection of PrPSc  
Spleens from scrapie infected mice were dissected at 3, 7, 14 and 30 days post 
inoculation (dpi) to determine the levels of PrPSc by western blotting (WB). Ten percent 
(w/v) homogenates were prepared for immunoblotting by ribolyzation.   
NaPTA precipitation and immuno-detection of PrPSc by western blot 
Sodium phosphotungstic acid (NaPTA) precipitation was performed as previously 
described (Wadsworth et al., 2001). All incubations were performed at 37 °C under 
CHAPTER 2  Material and Methods 
 56 
constant agitation at 800 rpm (Eppedorf Thermomixer). Briefly, 250 μl aliquots of 10 % 
spleen homogenate were mixed with 250 μl of 4 % sarkosyl (laurylsarcosine sodium 
salt) and incubated for 10 min. Samples were then treated with 1 μl benzonase and 
further incubated another 30 min. After centrifugation at 1000 rpm for 1 min, 
supernatant was collected and incubated for 30 min with 40.5 μl of a pre-warmed 
NaPTA-stock solution (4 % NaPTA + 170 mM MgCl2, pH 7.4) to give a final concentration 
of 0.3 % NaPTA. Following centrifugation at 14,000 rpm for 30 min, pellets resuspended 
in 20 μl of 0.1 % sarkosyl and digested for 1 h with 50 μg/ml PK.  
After PK digestion (50 μg/ml at 37 °C for 1 h), pellets were mixed 1:1 with 2× reducing 
sample buffer [125 mM Tris.HCl (pH 6.8), 20 % glycerol, 4 % SDS, 4 % 2-ME and 0.02 % 
Bromophenol Blue] and boiled at 100 °C for 10 min. Pre-stained Seeblue Protein 
Standard (Invitrogen, Paisley, UK) as molecular weight marker together with the 
various samples were loaded onto 16 % Tris-Glycine gels (Invitrogen, Paisley, UK) and 
electrophoresed for 80 min at 200 mV. Gels were blotted overnight onto PVDF 
membranes (Millipore, Watford, UK) pre-soaked in 100 % methanol at 15 V.  Blotted 
membranes were blocked for 1 h in PBST (PBS + 0.05 % Tween-20) and 5 % milk 
powder and then incubated for 2 h at room temperature (RT) with ICSM35 (1 mg/ml) 
diluted 1:500 in PBST. Secondary detection consisted of 1 h incubation at RT with 
alkaline-phosphatase-conjugated anti-mouse IgG (Sigma-Aldrich Company Ltd., Dorset, 
UK) diluted 1:10,000 in PBST. After each antibody incubation, membranes were washed 
6 times in PBST for at least 1 h. Bound antibody was detected using the 
chemiluminescent substrate CPD-Star (Tropix, Bedford, MA, USA) as previously 
described (Wadsworth et al., 2001); membranes were washed twice for 5 min in Tropix 
Assay buffer (20 mM Tris pH 9.8, 1 mM MgCl2), incubated for 2 min in CDP start, 
transferred to the photographic cassettes and visualized on Biomax MR film (Kodak, 
Hertfordshire, UK).  
 
CHAPTER 2  Material and Methods 
 57 
2.7 Fluorescence techniques 
2.7.1 Flow cytometry 
Isolated cell types were characterised by flow cytometry with fluorescence conjugated 
antibodies against specific cell surface markers. Briefly, aliquots of 1-2 Mio cells were 
resuspended in 100 μl MACS buffer and incubated with FcR blocking reagent 
(1:20, Miltenyi Biotech Ltd, Surrey, UK) for 15 min on ice to prevent non-specific 
binding. Samples were then stained with directly conjugated antibodies on ice for 
30 min and washed in MACS buffer to remove unbound antibody. Antibody 
specifications, including target cells and dilutions used, are detailed in table 2.1. 
Unconjugated and biotinylated antibodies (e.g. FDC-M1 & M2) required secondary 
staining with PE anti-rat IgG kappa (clone MRK1, BD Biosciences, Oxford, UK) and PE 
streptavidin (ebiosciences, Hatfield, UK), respectively. Cell viability of splenic cells after 
40 h in culture was assessed by incubation with 7-AAD (BD Biosciences Biosciences, 
Oxford, UK, 1:20 dilution) for 15 min before analysis.  
Cells were gated according to their forward and side scatter properties to exclude dead 
cells and debris. Unlabeled or isotype controls were used to locate the negative cells in 
the first quadrant, single labeled controls were used for compensation to minimize 
overlap of emission spectra. Data acquisition and analysis were performed using a 
FACS calibur and CellQuest software (BD Biosciences, Oxford, UK); alternatively, data 
analysis was done using the WinMDI v2.8 software.  
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Name Flurochrome Clone Isotype Target cell Company Dilution 
B220/CD45R FITC, PE RA3-6B rat IgG2a B cells, pDCs BD Biosciences 1:100 
CD90/Thy1.2 PE 30-H12 rat IgG2b, k T cells BD Biosciences 1:1000 
CD3 FITC K3T rat IgG2a T cells AbD Serotec 1:50 
CD11b PE M1/70 rat IgG2b Macrop, mDCs eBioscience 1:50 
CD11c FITC HL3 arm ham IgG1 DC BD Biosciences 1:100 
CD49b PE DX5 rat IgM, k NK, NK-T cells eBioscience 1:50 
Podoplanin/gp38 PE 8.1.1 syr ham IgG Fibroblasts Biolegend 1:250 
FDC-M1 purified FDC-M1 rat IgG2c, k FDC Gift Prof. Kosko   
FDC-M2 purified, biotin FDC-M2 rat IgG2a FDC ImmunoKontact  
CD21/CD35 FITC 76G rat IgG2b B cells, FDC BD Biosciences 1:100 
CD23/FcεRII PE B3B4 rat IgG2a, k B cells, macrop BD Biosciences 1:100 
CD86 PE GL1 rat IgG2a, k 
DC maturation 
marker BD Biosciences 1:100 
ICSM35 Biotin  ms IgG2b    
mPDCA-1 purified JF05-1C2.4.1 rat IgG2b pDCs Miltenyi Biotec  
  
Isotype controls: (purchased from eBioscience)  
FITC Arm Ham IgG isotype control 
Biotin Rat IgG2a Isotype control 
FITC Rat IgG2b Isotype control 
Rat IgG2b Isotype control 
PE Rat IgG2b Isotype control 
PE Rat IgG2a Isotype control 
Biotin Mouse IgG1, к Isotype control 
 
 
 
 
 
 
 
Table 2.1 List of primary antibodies and isotype controls used for cell characterization. 
 
Immune complex labeling 
The use of immune complexes (IC) to label FDCs was previously described by Sukumar 
et al., and it is based on the fact that FDCs retain ICs on their surfaces for long periods 
via FcR (Sukumar et al., 2008). Pre-complexed ICs were prepared by a 30 min 
incubation at 37 °C of chicken ovalbumin (OVA) (Sigma-Aldrich Ltd, Dorset, UK) and 
rabbit anti-chicken OVA (Sigma-Aldrich Ltd, Dorset, UK) at a ratio 6:1 prepared in PBS. 
Cells were then incubated in medium with pre-formed ICs (200 ng IgG / 1.2 μg OVA) 
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for 2 h on ice water. After thorough washing, half of the cells were transferred to a 
37 °C water bath for 30 min to favour internalisation, while the rest were kept on ice 
water at all times. ICs retained on the cell surface were labeled with Alx488 anti-rabbit 
IgG (Invitrogen, Paisley, UK) used at a 1:1000 dilution for 30 min on ice water. 
2.7.2 Fluorescence microscopy 
FDCs clusters were grown overnight on 13 mm round glass coverslips (VWR, West 
Sussex, UK) and stained with 10 ng/μl FDC-M1 or anti-rat IgG2b isotype control and 
2 ng/μl PE-conjugated anti-rat IgG kappa as secondary antibody. Following overnight 
incubation clusters were fixed onto the coverslips with 2 % paraformalhdehide (PFA) 
for 15 min at RT and incubated in superblock (Pierce, Leicestershire, UK) for 40 min. 
Primary and secondary antibody staining was done in MACS 0.5 % milk powder for 30 
min at RT. Clusters were washed three times between staining and analyzed in an 
Axioplan 2 fluorescent microscope (Carl Zeiss, UK).  
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KINETICS OF PRION ACCUMULATION IN SPLENIC CELL          
TYPES OF MICE 
In most transmissible spongiform encephalopathies (TSEs), prions accumulate in the 
lymphoreticular system (LRS) at early stages of the disease. This early replicative phase 
in the LRS is considered to be essential and to precede neuroinvasion (Eklund et al., 
1967; Kimberlin and Walker, 1989b). In the past two decades research focused on 
identifying the main cell types supporting replication and transport of prions from the 
periphery to the brain. Seminal work using immuno-deficient and PrP0/0 mice showed 
that both haematopoietic and stroma cells play fundamental roles in prion 
pathogenesis; follicular dendritic cells (FDC), B cells, macrophages and dendritic cells 
(DC) have been associated to different aspects of lympho-invasion including replication, 
dissemination and the clearance of prions (Klein et al., 1998; Beringue et al., 2000; 
Mabbott et al., 2000; Aucouturier et al., 2001; Kaeser et al., 2001; Prinz et al., 2002). 
The existence of the critical cell type that mediates neuroinvasion does not seem to 
hold true given the failure to fully prevent neuroinvasion in mouse models with specific 
immuno-deficiencies. Instead, it is generally accepted that prion propagation in the LRS 
is a dynamic process that depends on the interaction and contribution of different cell 
types (Aucouturier and Carnaud, 2002; Aguzzi et al., 2008).  
A comprehensive study to compare infectious titres in candidate cells has not been 
preformed to date, mainly due to limitations in the scope of in-vivo infectivity assays 
where prohibitively high numbers of mice are required. Developed a few years ago, the 
Scrapie Cell Assay (SCA), a cell-based infectivity assay greatly improves the titre 
determination; it is faster, cheaper and has a sensitivity comparable to the bioassay 
(Klohn et al., 2003).  
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Using sequential magnetic sorting and in-vitro infectivity testing, we here established a 
method to determine the rate of prion accumulation in representative cell populations 
of the spleen and investigated whether these cells release infectivity (i.e. exosomes) 
which could contribute to the dissemination of prions. We also aimed to address the 
contribution of the stroma compartment to prion titres in lymphoid organs.   
3.1 Quantification of infectious titres using a generalized linear model 
A reliable determination of prion titres is fundamental to the study of prion diseases 
where differences in titres may be critical to assess the efficacy of a therapeutic 
intervention or the outcome of an in-vitro perturbation on prion propagation. The SCA 
and its more sensitive format SCEPA are based on the microscopic detection of single 
PrPSc-positive cells that are formed de-novo by prion propagation after infection with 
prion-containing samples. In the standard assay (SCA), the proportion of PrPSc-positive 
cells is a function of the prion titre calculated from standard curves of brain 
homogenates of known titre. In SCEPA titres are determined at limiting dilutions of 
infectivity by the ratio of infected to total wells (Klohn et al., 2003; Mahal et al., 2008). 
The determination of titres by SCEPA is based on the assumption that the distribution 
of infected cells follows a Poisson distribution, but the validity of this assumption has 
not been verified previously. We now tested this assumption and propose a 
generalized linear model (GLM) to quantify prion titres. 
 
 
 
CHAPTER 3  Results 
 63 
3.1.1 Validation of a GLM for the estimation of infectious titres by SCEPA2
In the SCEPA prion titres are determined by the ratio of infected to total wells. At 
limiting dilution of infectivity the number of positive wells in nj independent infections 
at the jth dilution follows a binomial distribution with parameters nj and Pj where Pj is 
the proportion of positive wells. If the number of scrapie-infected cells is assumed to 
have a Poisson distribution then the proportion of negative wells (1- Pj) is equal to e-mcj 
where m is the mean number of infectious units per volume and cj the dilution. A 
complementary log-log transformation converts this equation to: 
 
Log (-log (1- Pj)) = log m + log cj      (1) 
Thus, if the experimental data follows a Poisson distribution then a complementary 
log-log transformation is linear with a slope of one.  
To check this hypothesis we prepared multiple dilution series of brain homogenate, 
infected susceptible cells and determined the number of negative wells. The brain 
homogenate RML I6200 was serially diluted 1:3 from 10-7 to 10-9 and cell layers of 12 
wells per dilution were infected using eight technical repeats per dilution (see 
appendices, table A1). Linear regression analysis resulted in an estimate of the slope of 
1.06 ± 0.20 (figure 3.1), in agreement with the assumption of an underlying Poisson 
distribution for the number of positive wells.  
 
                                                 
2 Statistical modelling to determine the relationship between the number of scrapie-infected cells and 
the infectious dose to calculate mean infectious units and variance was performed in cooperation with 
Professor Trevor Sweeting (Dept. Statistical Science, UCL).  
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Figure 3.1 Initial validation of Poisson distribution. To test whether the experimental data from in-vitro 
endpoint titrations follows a Poisson distribution, serial 1:3 dilutions of RML brain homogenate from 10-7 
to 10-9 were prepared and cell layers of 12 wells per dilution were infected. Complementary log-log 
transformed proportions of negative wells (1-Pj) vs. log dilutions of RML (log cj) are shown for eight 
technical assay repeats. Only data sets with proportions < 12 and > 0 positive wells were used for linear 
regression analysis, i.e. dilutions 10-8, 6.6 x 10-9 and 3.3 x 10-9 (see appendices, table A1). If the 
distribution of infected cells follows a Poisson distribution, the slope β is expected to be 1.  
 
This prompted us to calculate infectious titres using generalized linear model (GLM) 
regression, a statistical method first formulated by Nelder and Wedderburn (Nelder 
and Wedderburn, 1972) that unifies a wide range of probability distributions, 
comprising normal, binomial, Poisson, gamma, and others, generally known as 
‘exponential family distributions’ by the use of a common method for computing 
maximum likelihood estimates (see appendix 1). Ordinary regression analysis is based 
on normally distributed error components with constant variance and could lead to 
severe errors in the estimation of the outcome variable in case of non-normal 
distributions. GLM, however, permits the analysis of the linear relationship between 
the predictor and response variables, even when it is not reasonable to assume that 
the data is normally distributed.  
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Using the GLM approach, the proportion of positive wells (Pj) can be fitted by the 
regression model (1). This can be written as 
g(Pj) = α + βxj       (2) 
where g is the link function, a complementary log-log transformation, α the log mean 
infectious units, β the regression slope and xj the log dose. The link transformed 
proportions of positive wells using GLM were plotted in figure 3.2 and overlap with the 
linear regression analysis in figure 3.1. 
Parametres α and β are estimated by the maximum likelihood method 
(see appendix 2). An estimated value for β of 0.9608 ± 0.0969 is consistent with the 
hypothesis of an underlying Poisson distribution for the number of infected wells and 
the model provides a good fit to the data as estimated by an analysis of deviance 
(see appendix 2). An estimated titre (α) of 8.63 ± 0.03 log TCIU/g brain for eight 
technical repeats of serially diluted RML I6200 brain homogenate demonstrates the 
accuracy of the SCEPA.  
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Figure 3.2 Regression analysis of SCEPA endpoint titration assay by GLM. For the estimation of prion 
titres by SCEPA, prion-susceptible cells were infected with serially diluted RML I6200 brain homogenate 
and the proportions of scrapie-positive wells were analysed using a GLM with binomial family and 
complementary log-log link. (A) Observed and estimated proportions of scrapie-positive wells with 95 % 
confidence intervals. (B) Link-transformed proportions of scrapie-positive wells: g (Pj) = log (-log (1-Pj)). 
Data represent eight technical assay repeats of serially diluted RML I6200 brain homogenate. The four 
zero values at dilution 3.3 x 10-8 or -7.5 log dilution (see appendices, table A1) were replaced by 0.5 in 
order to plot the observed loglog values.  
 
3.1.2 Determination of the sensitivity of SCEPA 
Having established a GLM for the estimation of infectious titres, we applied this model 
to determine the sensitivity of SCEPA and aimed to establish a GML for bioassays to 
compare the sensitivity of both assays. Endpoint titrations of RML brain homogenate 
(I6200) by SCEPA using the highly susceptible PK1-2 subclone and mouse bioassay were 
performed in parallel experiments. Titres from eight independent in vitro assays were 
highly reproducible and yielded an estimated titre of 8.71 ± 0.04 by GLM (table 3.1). As 
a first estimate to compare sensitivities we calculated the median infectious titres using 
the Spearman-Karber method (Dougherty, 1964). Eight independent cell-based assays 
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yielded a titre of 8.70 ± 0.19 log LD50/g brain and the combined two independent 
bioassays a titre of 9.14 ± 0.28, in agreement with previously published titres for I6200 
(Cronier et al., 2008) (table 3.1).  
To implement a GLM for bioassay, data from five independent bioassays with RML 
I6200 (from Dr Malin Sandberg MRC Prion unit, London) were fitted by GLM using a 
complementary log-log or a probit transformation as link functions (see appendix 1). 
The link-transformed proportions of scrapie-sick mice by both models were plotted in 
figure 3.3. A probit model yielded a titre of 8.71 ± 0.53 log LD50 units/g brain and the 
complementary log-log model a titre of 8.54 ± 0.54 log LD50 units /g brain. Using the 
Spearman-Karber method a corresponding titre of 8.66 ± 0.80 log LD50 units/g brain 
was determined. The obtained titres for RML I6200 are unexpectedly lower compared 
to data of table 3.1 and previously published data (Cronier et al., 2008). The observed 
variations of infectious titres between brain homogenates is most likely results from 
differences in the dispersion state of homogenates, an issue that will be addressed in 
the next section, or multiple freezing-thawing cycles (Properzi et al., unpublished). 
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Figure 3.3 Regression analysis of mouse bioassay data by GLM. Data from five independent bioassays 
with RML I6200 was analysed by a GLM with binomial family complementary log-log (A) and probit (B) 
link functions. The left graphs represent the observed and estimated proportions of scrapie-sick mice 
with 95 % confidence intervals. The right graphs show the linearised link-transformed proportions of 
scrapie-sick mice. 
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By using GLM and comparing sensitivities of the infectivity assays in parallel 
experiments (table 3.1) we conclude that the sensitivity for prion detection by SCEPA 
(8.71 ± 0.04 log TCIU/g) was not significantly different from the combined mouse 
bioassay data (9.02 ± 0.23 LD50 units/g) given the high inter- and intra-assay variability 
of the bioassay. The high standard error in titre estimations from bioassays 
compromises a direct comparison between in-vitro and in-vivo assays. Despite the lack 
of statistical significance the bioassay seems to be more sensitive than SCEPA as shown 
in subsequent experiments (table 3.2). While the SCEPA outperforms the mouse 
bioassay in terms of statistical robustness, low cost and fast infectivity testing, the 
bioassay will be indispensable where prion titres are below the detection limit of the 
SCEPA (2 LD50/g brain or spleen homogenates and 1-5 LD50/106 cells, respectively, 
based on infectious titres determined at clinical end-stage). In addition, N2a derived 
cells are permissive to prion strains RML and 22L only, but not to other mouse adapted 
prion-strains like ME7, 22A and 301C. It should noted, though, that the sensitivity of 
the SCEPA is cell-type dependent. 
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 RML input in LD50 units
# 
SCEPA* Mouse bioassay 1 Mouse bioassay 2 
PrPSc-positive 
/total wells 
Sick/ total Incub.time, days ± SD Sick/ total 
Incub.time, 
days ± SD 
 6x103 n.d 5/5 75.8 ± 1.2 n.d n.d 
 6x102 n.d 5/5 83.2 ± 3.6 5/5 86.2 ± 2.8 
 6x101 24/24 6/6 106.5 ± 6.4 5/5 112.6 ± 5.9 
 6x100 15/24 3/4 110.3 ± 4.0 3/5 122.3 ± 6.3 
 6x10-1 2/24 1/5 116 1/5 104 
 6x10-2 0/24 2/6 159.5 ± 1.0 1/6 136 
 6x10-3 n.d 0/6 >200 0/6 >200 
 Infectious titres Log TCIU/g ± SE Log LD50/g ± SE Log LD50/g  ± SE 
 Spearman-Karber 8.71± 0.19 9.31 ± 0.42 8.99 ± 0.41 
 GLM 8.71 ± 0.04 9.02 ± 0.23‡ 
# Prion infectivity of input (RML I6200) is based on a previous endpoint titration (Cronier et al., 2008). 
*The ratio between PrPSc-positive and total wells is shown for one representative out of eight experiments.  
 ‡Infectious titres were estimated for the combined two bioassays using a GLM regression with probit link function and 
expressed as log LD50 units/g brain. 
Table 3.1 Sensitivity for prion detection of SCEPA and mouse bioassay. The sensitivity for prion 
detection of SCEPA and mouse bioassay was determined by end-point titration using RML mouse brain 
homogenate I6200. Aliquots of 10 % (w/v) I6200 (9.3 logLD50/g brain, Cronier et al., 2008) were serially 
diluted 1:10 into uninfected CD1 brain homogenate (10 %, w/v) in a range between 10-4 and 10-10. For 
mouse bioassay, groups of six Tga20 mice were inoculated intracerebrally with 30 μl of 1 % (w/v) 
homogenates and attack rates and scrapie incubation times were determined. In parallel experiments, 
brain homogenates were diluted 1:1000 into OFCS and cell layers of highly prion susceptible N2aPK1-2 
cells were infected with 300 μl aliquots. The input of RML infectivity for bioassay and SCEPA is expressed 
as LD50 units and was calculated from previous published titre (Cronier et al., 2008) for each dilution and 
volume used in the infection, e.g. a 10-7 dilution of I6200 corresponds to 200 LD50 units/ml or 6x10
0 LD50 
units per 30 μl inoculum for the bioassay and 6x101 LD50
 units per 300 μl per well for SCEPA, respectively. 
Infectious titres for SCEPA and bioassay were determined using both Spearman-Karber and GLM and 
expressed as log TCIU/g brain ± SE of 8 independent experiments and log LD50 units/g brain ± SE for 2 
independent bioassays, respectively.  
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3.2 Validation of a homogenization method for cell titre determination 
by SCEPA 
The dispersion state of the homogenate is a critical parameter for titre determination 
by endpoint titration, since an increase in the dispersion of infectious brain 
homogenate results in an apparent increase of infectivity at limiting dilutions. The 
determination of infectious titres by the standard SCA has been validated for scrapie-
infected brain homogenates, but not for homogenates of splenic cell isolates. We 
therefore aimed to establish a standardised method for tissue cell homogenisation and 
confirmed its suitability for prion determination by SCEPA.  
Homogenisation by shear force with needles, a method broadly used to generate tissue 
homogenates, failed to homogenise splenocytes as indicated by a high percentage of 
Trypan blue-negative viable cells. We therefore tested two alternative homogenisation 
methods, sonication and ribolysation which both led to a complete disruption of cells. 
To determine infectious titres for isolated immune cells from scrapie-infected mice 
whole cells or cell homogenates were inoculated previously (Raeber et al., 1999a; 
Aucouturier et al., 2001). The uptake of infectious particles by susceptible cells may 
also depend on the particle size of the infectious entity and the number of infectious 
particles per volume. Preliminary experiments showed a significant difference between 
the infectious titres of MACS-isolated plasmacytoid DCs (pDC) and B cells. We therefore 
assessed the suitability of cell homogenisation methods using both cell types by 
determining infectious titres using mouse bioassay and SCEPA (table 3.2).  
Infectious titres of B cells determined by mouse bioassay at 30 dpi were in agreement 
with previously published data from a similar experiment with RML and the same 
mouse strain (Raeber et al., 1999a). Cell titres were about one log higher in the 
bioassay as compared to SCEPA, consistent with a reduced sensitivity of SCEPA. No 
significant differences in infectious titres were observed between the two 
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homogenisation methods for both cell types using SCEPA and bioassay, respectively. 
Remarkably, titres for pDCs were consistently higher than those of B cells, irrespective 
of the homogenisation method and the infectivity assay used. Estimates by GLM 
showed that titres of pDCs were significantly higher (p < 0.005) than those of B cells 
when assayed by SCEPA. Although similar estimates of the prion titre were calculated 
by either Spearman-Karber formula or GLM, higher variances were associated to 
Spearman-Karber estimations as compared to the GLM.   
For all subsequent experiments ribolyzation was used as preferred homogenisation 
method to exclude the risk of cross-contamination during sonication of prion-infected 
samples (Barria et al., 2009) .   
CHAPTER 3  Results 
 73 
 (A) SONICATION 
 
Cell 
Types 
Cell number 
equivalents‡ 
SCEPA Mouse bioassay 
 PrPSc-positive 
/total wells 
Attack 
rate 
Incub.time, 
days ± SD 
 pDC 6x103 12/12 5/5 89 ± 1 
  6x102 5/12 5/5 117 ± 9 
  6x101 1/12 2/6 131 ± 17 
  6x100 0/12 0/6 > 200 
 control 6x103 0/12 0/6 > 200 
 Infectious titres Log TCIU/106 cells ± SE Log LD50/10
6 cells ± SE 
 Spearman-Karber 3.21 ± 0.08 4.06 ± 0.25 
 GLM 3.13 ± 0.04 (p < 0.005)* - 
 B cells 6x104 12/12 5/5 92 ± 4 
  6x103 8/12 6/6 99 ± 2 
  6x102 2/12 5/6 124 ± 7 
  6x101 0/12 1/6 171 
 Control 6x104 0/12 0/4 > 200 
 Infectious titres Log TCIU/106 cells ± SE Log LD50/10
6 cells ± SE 
 Spearman-Karber 2.61 ± 0.19 3.72 ± 0.30 
 GLM 2.53 ± 0.03 - 
 (B) RIBOLYZATION 
 
Cell Types 
Cell number 
equivalents‡ 
SCEPA Mouse bioassay 
 PrPSc-positive 
/total wells 
Attack 
rate 
Incub.time, 
days ± SD 
 pDC 6x103 12/12 4/4 85 ± 1 
  6x102 6/12 5/6 105 ± 5 
  6x101 1/12 4/6 108 ± 8 
  6x100 0/12 0/6 > 200 
 Control 6x103 0/12 0/4 > 200 
 Infectious titres Log TCIU/106 cells ± SE Log LD50/10
6 cells ± SE 
 Spearman-Karber 3.31 ± 0.15 4.22 ± 0.33 
 GLM 3.24 ± 0.04 (p < 0.005)* - 
 B cells 6x104 12/12 6/6 88 ± 3 
  6x103 9/12 5/5 100 ± 5 
  6x102 2/12 5/5 107 ± 12 
  6x101 0/12 1/5 174 
 Control 6x104 0/12 0/3 > 200 
 Infectious titres Log TCIU/106 cells ± SE Log LD50/10
6 cells ± SE 
 Spearman-Karber 2.70 ± 0.15 3.92 ± 0.29 
 GLM 2.53 ± 0.03 - 
‡Inputs of infectious cell homogenates are expressed as cell number equivalents.  
*Level of significance for maximum likelihood estimates (GLM) between infectious titres of 
pDCs versus B cells as determined by SCEPA. 
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Table 3.2 Infectious titres of MACS-isolated cells after homogenization by ribolyzation and sonication. 
Four 129/Sv x C57BL/6 mice were inoculated i.p. with 100 μl 1 % RML infected brain and uninfected CD1 
brain homogenate (control), respectively. At 30 dpi spleens were dissected and pDCs and B cells isolated 
by MACS according to Figure 2.1 (section 2.1.1). Aliquots of 2 x 107 cells/ml OFCS, supplemented with 
protease inhibitors were homogenised by sonication (A) or ribolysation (B) according to material and 
methods (section 2.2.2). To determine infectious titres, cell homogenates were serially diluted 1:10 and 
inoculated intracerebrally into Tga20 mice or transferred onto layers of susceptible PK1-2 cells in parallel 
experiments. A 10-2 dilution of cell homogenates corresponds to 2 x 105 cell equivalents/ml or 6 x 103 cell 
equivalents per 30 μl inoculum for mouse bioassay and 6 × 104 cell equivalents per 300 μl per well for 
SCEPA. Infectious titres were determined by non-parametric statistical analysis for bioassay (Spearman-
Karber) and GLM for SCEPA and expressed as log LD50 units/10
6 cells and log TCIU/106 cells, respectively. 
 
3.3 Sequential isolation of splenic cell types by magnetic-activated cell 
sorting 
To address the contribution of specific cell types to prion accumulation in the spleen 
we designed and optimized a cell separation protocol based on sequential rounds of 
positive selection using antibody-coated magnetic microbeads that enables the 
isolation of B cells, T cells, DCs, pDCs, macrophages and natural killer (NK) cells from 
the same pool of splenocytes, and determined infectious titres subsequently. Using this 
approach sufficient numbers of cells for infectivity testing can be isolated from spleens 
of scrapie-infected mice with high purities and within a reasonable time. For the 
isolation of DCs, for example, 4 x 108 splenocytes were processed in about an hour with 
an average yield of 3-4 % i.e. 12-16 Mio cells (table 3.3), and magnetic isolation of up to 
6 different cell types was performed in about five hours.  
From a mixed population of cells released by enzymatic digestion of freshly dissected 
spleens, individual cell subsets were purified in sequential rounds of positive selection 
with magnetic beads directed against specific surface markers in the target cells 
according to the sorting strategy depicted in figure 2.1, material and methods. Isolation 
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protocols were optimised against cell yields and purities aiming to reduce 
experimentation times as possible, e.g. rare populations such DCs and NK cells were 
isolated first to minimize cell losses associated to successive positive selections. During 
the implementation of a sorting strategy we also considered cases where a surface 
marker was expressed at low levels or on more than one cell type. For example, three 
main subsets of DCs in murine spleens can be distinguished by means of their surface 
markers: CD11c+CD11b+ myeloid DCs (mDC), CD11c+ CD8+ lymphoid DCs (lDC) and 
CD11clow B220+ pDCs (Bjorck, 2001). Since low expression levels of CD11c on pDCs may 
compromise their quantitative isolation with CD11c microbeads, we used microbeads 
coated with murine plasmacytoid dendritic cell antigen-1 (mPDCA-1) which is 
specifically expressed on pDCs of murine spleen (Krug et al., 2004). Accordingly, pan-
DCs were isolated using a 2:1 mixture of CD11c and mPDCA-1 microbeads to ensure 
that all DC subsets were equally represented in the pan-DC fraction. Highly purified cell 
fractions with purities from about 87 % for rare cells (DCs and pDCs) to more than 95 % 
purity for lymphocytes subsets (B cells, T cells and NK cells) were obtained using this 
isolation strategy (figure 3.4).  
Widely used for the isolation of macrophages, CD11b surface antigen is expressed not 
only on macrophages but also on mDCs (CD11c+ CD11b+).  In an effort to avoid an 
enrrichment of mDC contaminants in the macrophage fraction, we proposed two 
positive selection rounds with CD11c microbeads to deplete DCs before the isolation of 
macrophages (figure 2.1, material and methods). However, this did not suffice to 
deplete mDCs that were still capture for CD11b beads (figure 3.4 F). A depletion 
strategy using Miltenyi depletion columns and CD11c microbeads, although gave better 
results (data not shown), was not considered since it would increase the number of 
mice needed and the costs of the cell sorting with MACS reagents considerably. 
Instead, we used fluorescence-activated cell sorting (FACS) to obtain a highly purified 
CD11c- CD11b+ macrophage cell population (figure 3.5).  
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Spleen weight 72 ± 9 mg 
Splenocytes 116 ± 9 x 106 cells per spleen 
Cell types Microbeads Yield Surface marker Purity  
pDCs mPDCA-1 3.8  % CD11c+ B220+ 87 % 
pan DCs CD11c + mPDCA-1 3.3 % CD11c+ 90 % 
Macrophages CD11b 1.9 % CD11c- CD11b+ 74 % 
B cells CD19 33 % B220+ 99 % 
T cells CD90 13 % CD3+ 98 % 
NK CD49b 3 % CD49b+ 97 % 
 
Table 3.3 Summary of yields and purities of isolated splenic cell types. The number of cells was 
estimated from 3 to 6 independent counts using a Coulter counter Z2 (Beckman Coulter, High Wycombe, 
UK) and expressed as % yields (=number of sorted cells/number of total cells). The purity of the fractions 
was evaluated by flow cytometry using monoclonal antibodies (mAbs) against to CD11c (clone HL3), 
CD11b (clone M1/70), B220 (clone RA3-6B), CD49b (clone DX5) and CD3 (clone KT3). Data is 
representative of at least 5 experiments.  
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Figure 3.4 Flow cytometric analyses of isolated splenic cell types. Different splenic cell populations were 
isolated by sequential MACS as described in material and methods (section 2.1.2). Purities of the isolated 
cell fractions were assessed by flow cytometry in a FACScalibur (BD Biosciences, Oxford, UK) using the 
following monoclonal antibodies (mAbs): (A) anti-B220 for B cells, (B) anti-CD90 for T cells, (C) anti-CD11c 
for DCs and (D) anti-CD49a for NK and NK-T cells. Shaded histograms represent cell-specific mAbs, open 
histograms negative controls. (E) PDCs isolated with mPDCA-1 microbeads are CD11c+ B220+ with purities 
of 87 %. (F) CD11b+ CD11c- Macrophages isolated with CD11b microbeads after depletion of CD11c+ cells 
in the upper-left quadrant have a purity of 74 %, the macrophage-enriched fraction also contained about 
19 % mDC contaminants. Representative results of at least three experiments are shown. The 
percentage of positive cells is indicated in each of the graphs.  
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Figure 3.5 Purification of macrophages by fluorescent activated cell sorting. (A) CD11b+ myeloid cells, 
containing CD11b+ CD11c- macrophages and CD11b+ CD11c+ mDCs were isolated from total splenocytes 
by magnetic cell sorting with CD11b microbeads. (B) Macrophages were sorted by flow cytometry in a 
MoFlo (Dako, Cambridgeshire, UK) with mAbs against CD11c and CD11b. Sorted CD11c- CD11b+ 
macrophages are shown in 3.2 A. 
 
3.4 Prion accumulation in the lymphoreticular system at early stages of 
prion disease 
Early studies have addressed the evolution of prion titers in different lymphoid organs 
after inoculation by different routes and showed that prions accumulate and replicate 
in spleen and lymphoid nodes reaching plateau levels early after inoculation (Eklund et 
al., 1967; Kimberlin and Walker, 1979; Millson et al., 1979). However, the contribution 
of specific immune cells to prion titres in the LRS is not well characterised as previous 
studies were restricted to single time points and a few cell subsets. We here examined 
the kinetics of prion accumulation in tissue and cells of the LRS during the rapid 
replication phase before maximum titres are reached (i.e. 30 dpi).  
To assess the rate of prion accumulation in lymphoid tissues, prion titres in spleen and 
mesenteric lymph nodes (MLN) of 129Sv-C57/BL6 wid-type and Prnp-/- mice were 
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measured over the first month post inoculation. Groups of ten mice were inoculated 
intraperitoneally with 1 % RML corresponding to an infectious dose of 5.7 log LD50 units 
(table 3.1) and culled at 3, 7, 14 and 30 dpi. Ten percent homogenates (w/v) were 
prepared by ribolysation (see materials and methods, section 2.5.2) and analysed for 
infectivity. Prion replication in spleen was evident as early as 3 dpi, where 
5.4 log TCIU/g spleen were detected in wt mice as compared to 2.5 log TCIU/g spleen in 
Prnp-/- mice, corresponding to an 800-fold difference in titres (figure 3.6 A). 
Accumulation of prions in MLN was delayed as compared to spleen in accordance to 
previous reports (Kimberlin and Walker, 1989b). No infectivity was detected in MLN at 
3 dpi at the range of dilutions tested (< 2.5 log TCIU/g) and prion titres were 
consistently lower as compared to spleens throughout the studied time period 
(figure 3.6 A). In contrast to the in-vitro determination of infectivity by SCEPA, PrPSc 
was not detectable on Western blot at time points prior to 14 dpi corresponding to 
titres of 6.5 log TCIU/g (figure 3.6 B), highlighting the limitations of PrPSc detection for 
diagnostic purposes. Infectivity reached 7.2 log TCIU/g and 6.7 log TCIU/g tissue at 30 
dpi in spleen and MLN, respectively.   
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Figure 3.6 Kinetics of prion accumulation in spleen and mesenteric lymph nodes. (A) Wild-type and 
Prnp-/- mice were inoculated i.p. with 5.7 log TCIU  RML prions and culled at 3, 7, 14 and 30 dpi to 
retrieve spleens and mesenteric lymph nodes (MLN). Infectious titres of tissue homogenates, 
determined by SCEPA were analyzed by a GLM. Dark circles: spleen tissue; empty circles: MLN tissue; 
black square: spleen tissue of Prnp-/- mice. (B) Samples from four spleens (1-4) were analyzed for PrPSc at 
each time point. An equivalent to 25 mg wet weight of tissue was precipitated with NaPTA, digested with 
PK (50 μg/ml at 37 °C for 1 h), and immunoblotted with the monoclonal anti-PrP antibody ICSM35 as 
described in material and methods (section 2.5.4). 
 
Upon i.p inoculation of Prnp-/- mice with 100 μl 1 % RML I6200 (5.7 log TCIU, table 3.1), 
about 1.2 log TCIU/spleen were detected at 3 dpi at an average weight of 72 ± 9 mg. In 
contrast, no infectivity was detected in MLN of Prnp-/- mice, suggesting that following 
i.p inoculation prions are transported first to the spleen. We next investigated whether 
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infectivity from the inoculum was associated to specific splenic cells (table 3.4). Titres 
reached the detection limit of SCEPA, infectivity seemed to be associated primarily to 
antigen presenting cells (APC), i.e. macrophages, DCs, and lymphocytes. This is 
consistent with a role of APCs in prion sequestration.   
  
 TCIU/106 cells ± SE#  ‡Myeloid cells contained  mainly macrophages 
(CD11b+ CD11c-) and about 20 % myeloid DC 
(CD11c+ CD11b+) contaminants. 
#Infectious titres calculated by the GLM are 
represented as mean values ± SE for at least 
three independent experiments. 
Cell Types 3 dpi  
Pan DC 0.23 ± 0.09   
Myeloid cells‡ 0.47 ± 0.17  
B cells 0.06 ± 0.06  
T cells 0.06 ± 0.06  
Table 3.4 Infectious titres of different splenic cell types in the absence of prion replication at 3 dpi. 
Different cell types were isolated by magnetic sorting from spleens of Prnp-/- mice three days after 
intraperitoneal inoculation with RML prions. Infectious titres were determined by SCEPA and analyzed by 
GLM.  
 
We next determined infectious titres of major splenic cell types and their rates of prion 
accumulation. Infectivity was detectable in all cell types as early as 3 dpi and increased 
rapidly over time. In splenocytes a 50-fold increase in cellular titres was determined on 
average between 3 and 30 dpi (table 3.5), consistent with the increase of infectious 
titres in spleen during the same time interval (figure 3.6 A).  
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 Infectious titres:      TCIU/106 cells ± SE    (95 % confidence interval)# 
Cell Types 3 dpi 7 dpi 14 dpi 30 dpi 
Splenocytes 11 30  265 ± 64  (147,480) 544 ± 124  (311,952) 
Pan DC 23 62 ± 14  (36,107) 265 ± 64  (147,480) 677 ± 87  (518,858) 
pDC 41 106  370 ± 85  (211,650) 1798 ± 298  (1252,2579) 
Myeloid cells‡ 1 37 ± 9  (23,62) 127 ± 34  (67,244) 472 ± 57  (365,609) 
Macrophages† n.d n.d  n.d  243 ± 49  (157,375) 
B cells 9 26 ± 6  (16,43) 130 ± 35  (68,249) 262 ± 28  (210,328) 
T cells 9 25 ± 6  (15,42) 135 ± 36  (71,260) 208 ± 28  (156,279) 
NK/T cells* n.d n.d  183  721 ± 120 (491,1059) 
pDC (blood) n.d n.d  n.d  < 6  
‡Myeloid cells were isolated with CD11b magnetic microbeads after partial depletion of CD11c+ DCs, it consisted 
mainly of macrophages (CD11b+CD11c-) and around 20 % myeloid DC (CD11c+CD11b+) contaminants (see 
figure 3.5).   
†CD11b+ macrophages devoid of mDCs were isolated by FACS (see figure 3.4).  
*NK and NK-T cells were isolated with CD49b magnetic beads. 
#Infectious titres are represented as mean values ± SE, and as lower and upper limits of 95 % confidence 
intervals.   
Table 3.5 Time dependent accumulation of prion infectivity in isolated splenic cell types. Groups of ten 
129Sv x C57/BL6 mice, inoculated i.p. with 100 μl aliquots of 1 % (w/v) RML brain homogenate I6200 
were culled at various time points after inoculation. Splenocytes and splenic cell types were isolated 
from spleens by MACS after collagenase digestion and lympholyte purification. Infectious titres were 
determined by SCEPA using a GLM.  
 
Whilst prions were detectable in all cell types, including lymphocytes, NK cells, DCs and 
macrophages, highest infectious titres were determined in two cell types that have 
previously not been associated to prion pathogenesis, pDC and NK cells. At 30 dpi, pDCs 
were 7-8 fold more infectious than lymphocytes and macrophages, and 2-fold more 
infectious than NK cells. Prion titres of NK cells were also significantly higher (p < 0.05) 
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than those of lymphocytes and purified macrophages. In addition to pDCs, pan DCs 
accumulated high prion titres (figure 3.7).  
 
Splenocytes
Plasmacytoid DC
pan DC
Myeloid cells
Macrophages
B cells
T cells 
NK/T cells
0 300 600 900 1200 1500 1800 2100
Infectious titres  (TCIU/106 cells)  
Figure 3.7 Distribution of infectivity in splenic cell types at 30 dpi. Infectious titres at 30 dpi from 
table 3.4 were re-plotted for clarity. Significant differences between pDCs, panDCs and NK/T cells and B 
cells, macrophages and T cells are indicated (* for a p < 0.05 or ** for a p < 0.001).  
 
In an attempt to understand the participation of highly infectious pDCs on prion 
colonisation of the LRS, we examined the effect of pDC depletion on prion titres in 
spleen and MLNs. Previous studies have shown that administration of anti-mPDCA-1 
can efficiently deplete pDCs in vivo (Krug et al., 2004; Bailey-Bucktrout et al., 2008). 
Groups of four mice were injected i.p. with 250 μg anti-mPDCA-1 or an isotype control 
before and after i.p. inoculation with prions. Injections were done every 2-3 days to a 
total of 8 injections covering most of the incubation period until the animals were 
culled at 19 dpi. Of note, the experiment was not controlled for the level of pDC 
depletion during the assayed period and can only be considered as preliminary. 
* 
* 
* 
* 
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Nevertheless, prion titres of MLNs were reduced by one log in pDC-depleted mice as 
compared to isotype control antibody-treated mice (table 3.6) suggesting that pDCs 
may somehow contribute to the prion titres in lymph nodes. No effect, however, was 
detected on splenic prion titres (table 3.6).  
 
129Sv x C57B/6 
mice 
Spleen Mesesenteric lymph nodes 
Control Treated Control Treated 
(log TCIU/g) (log TCIU/g) (log TCIU/g) (log TCIU/g) 
1 7.04 6.37 5.29 4.33 
2 6.78 6.76 4.86 4.42 
3 6.25 7.25 5.78 3.46 
4 6.13 6.47 5.20 4.66 
Mean titre ± SD 6.70 ± 0.28 6.86 ± 0.30 5.41 ± 0.28 4.38 ± 0.24 
Table 3.6 Effects of in vivo depletion of pDCs on prion titres of spleen and mesenteric lymph nodes.  
Before and after i.p inoculation with RML prions four mice per group were treated either with mPDCA-1 
antibodies (treated) showed to deplete pDCs in vivo, or with the appropriated isotype control (control) as 
described in the main text. Animals were culled at 28 dpi to determine infectious titres of MLNs and 
spleens.  
 
The high infectious titres of pDCs prompted us to investigate whether pDCs fulfil the 
criterion for prion-propagating cells. The expression of PrPC, a pre-requisite for prion 
replication, was reportedly undetectable (del Hoyo et al., 2006) or lower (Rybner-
Barnier et al., 2006) in pDCs as compared to other DCs in C57BL/6 mice. To exclude 
mouse strain-dependent differences in PrPC expression levels, we determined the 
levels of PrPC expression on pDCs. In agreement with previous reports (del Hoyo et al., 
2000), PrPC expression was undetectable arguing against a direct role of pDCs in prion 
replication (figure 3.8).  
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Figure 3.8 PrPC expression of splenic pDCs. PDCs isolated from spleens of uninfected 129/Sv x C57BL/6, 
or Prnp-/- mice used as control, were analyzed by flow cytometry for PrPC expression with biotinylated 
anti-PrP monoclonal antibody ICSM35. Allophycocyanin (APC)-conjugated streptavidin was used as 
secondary label. As a control for PrPc expression mouse neuroblastoma cells (N2a) were labeled with 
biotinylated ICSM35 and biotinylated mouse IgG2b isotype control. 
 
Prion infectivity was detected at extremely low titres in blood of rodents at 
presymptomatic and symptomatic stages and were associated with plasma and buffy 
coat fractions (Brown et al., 1998; Castilla et al., 2005a; Tattum et al., 2010). In a 
previous report infectivity was not detected in peripheral blood leukocytes in 
129/Sv x C57BL/6 mice at early stages of disease regardless of relatively high titres in B 
and T lymphocytes of the spleen (Raeber et al., 1999a). Given the high infectious titres 
of DCs and pDCs we examined whether prion infectivity is associated to pDCs in blood. 
Although recirculation of DCs is greatly limited as compared to lymphocytes, evidence 
for recirculation under steady-state condition has been reported (Bonasio and von 
Andrian, 2006). The migratory pattern of pDCs greatly varies from convectional DCs, 
most reports support the view that pDCs enter the lymph nodes via the bloodstream 
(Randolph et al., 2008). To determine whether prion infectivity is associated to pDCs in 
the blood we isolated pDCs from EDTA-treated whole blood. However, no infectivity 
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was associated with pDCs (table 3.5), lymphocytes and DCs (data not shown) from 
blood at 30 dpi under our experimental conditions. 
Despite lymphocytes actively recirculate in steady-state conditions, no infectivity was 
detected lymphocytes isolated from blood (Raeber et al., 1999a; our own observation) 
suggesting prion infected B cells are somehow confined in lymphoid organs. 
Interestingly, a recent study showed an abnormal germinal centre reaction in the 
spleen of scrapie-infected mice which was associated with increased maturation and 
numbers of B lymphocytes and hypertrophy of FDC dendrites in at 70 dpi and endstage 
(McGovern et al., 2004). To examine whether prion related changes in splenic B cell 
subsets were detectable at preclinical stages, groups of three age-matched mice were 
inoculated i.p. with 1 % RML infected or uninfected CD1 brain homogenate and culled 
at 30, 80 and 100 dpi. Splenocytes were analysed by three-color FACS for CD19, CD21 
and CD23. However, no changes were detected in the ratios of marginal zone B cells 
(CD21hi CD23-) and follicular B cells (CD21int CD23hi) (figure 3.9). 
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Figure 3.9 No abnormalities of splenic B cell subsets at preclinical disease. 129Sv x C57BL/6 mice were 
inoculated i.p. with 100 μl 1 % RML I6200 or 100 μl 1 % uninfected CD1 homogenate and culled at 80 dpi 
(A) and 100 dpi (B). Splenocytes were isolated according to materials and methods (section 2.1.1). To 
analyse B cell subsets splenocytes were labelled with mAbs against anti-CD19, anti-CD23 and anti-CD21. 
The CD19-gated B cell population was examined for CD21/35 and CD23 expression. Figures are 
representative of three independent experiments. 
 
3.5 Contribution of the stromal compartment 
A wealth of evidence indicates that stromal cells play a fundamental role in prion 
pathogenesis (Clarke and Kimberlin, 1984; Fraser and Farquhar, 1987; Fischer et al., 
1996). In particular, follicular dendritic cells (FDC) are considered prime candidates for 
prion replication in the LRS as inferred from studies where temporal depletion of FDCs 
abolished prion accumulation in the spleen and prolonged incubation times (Mabbott 
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et al., 2000; Montrasio et al., 2000). Other stromal cell types, presumably fibroblastic 
reticular cells were shown to support prion replication when FDCs are absent, as shown 
for granulomas (Heikenwalder et al., 2008). Macrophages that accumulate abnormal 
PrP in TNFR1-/- lymph nodes were also suggested alternative replication sites (Prinz et 
al., 2002). 
The contribution of the stromal compartment to prion replication has been addressed 
previously. In these studies the separation of splenic pulp from the stromal tissue was 
achieved by forcing spleens through a mesh and by repeatedly flushing out pulp cells 
using a syringe, respectively (Clarke and Kimberlin, 1984; Raeber et al., 1999a; Kaeser 
et al., 2001). Clarke and Kimberlin showed that about ten-fold higher titres were 
associated to the stromal, as compared to the pulp fraction of the spleen (Clarke and 
Kimberlin, 1984). The accumulation of disease-specific PrP was detected extracellularly 
on FDC membranes (Kitamoto et al., 1991; Jeffrey et al., 2000), suggesting that 
infectivity in the stromal compartment is most likely associated with these cells. 
However, infectious titres have not been determined for FDCs. 
Whilst in the previous section we determined the contribution of the haematopoietic 
cell types to total prion titres in spleen, we now aimed to determine the titres of 
stromal FDCs in wt and Prnp-/- mice. In addition, we established an in-vitro model to 
study the involvement of the stromal compartment in prion pathogenesis by setting up 
heterogeneous stromal cultures from spleens of scrapie-infected mice and investigated 
their propensity to propagate prions. 
3.5.1 Isolation of follicular dendritic cells 
“I have not failed. I've just found 10,000 ways that won't work.“     Thomas A. Edison  
The isolation of FDCs for the determination of infectious titres poses major challenges. 
FDCs are rare (1 in 10,000 cells) and highly connected cells with long dendritic 
processes, tightly anchored to reticular fibres. They are intimately associated with 
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B cells to form FDC-B clusters (Schnizlein et al., 1985). Standard isolation methods for 
FDCs include immunization and sublethal irradiation of mice to boost the number of 
germinal centres and to deplete lymphocytes, respectively (Kosco-Vilbois et al., 1993). 
However, we refrained from adapting these protocols, since these are likely to have 
profound effects on prion titres (Dickinson et al., 1978; Fraser and Farquhar, 1987).  
A critical step to successfully isolate FDCs is the gentle and complete disaggregation of 
stroma tissue by enzymatic digestion (Schnizlein et al., 1985). Once released from 
tissue FDCs were enriched on a density gradients (FDCs float at densities around 
1.06-1.05 g/ml), followed by the removal of fibroblasts and myeloid contaminants by 
adhesion to plastic (Schnizlein et al., 1985). Alternative protocols for the enrichment of 
FDCs exploit the formation of clusters between FDCs and lymphocytes immediately 
after isolation (Kosco et al., 1992). The separation of FDC clusters from single cells can 
be achieved by consecutive 1 x g sedimentations (Tsunoda et al., 1990). MACS isolation 
was used as a more specific method to isolate FDCs (Schmitz et al., 1993; Sukumar et 
al., 2006). A purity of up to 90 % was reported for the isolation of murine FDCs by 
MACS when used in combination with immunization and irradiation protocols 
(Sukumar et al., 2006).  
Based on established protocols, we attempted to isolate FDCs from spleens of 
non-immunized, non-irradiated mice as depicted in figure 3.10 A. After extensive 
enzymatic digestion of spleen tissue, released cells were loaded onto discontinuous 
gradients. Low-density cells contained high numbers of cell clusters as confirmed by 
microscopy (figure 3.10 C). Low-density cells labelled with mAbs anti-FDC-M1 and anti-
FDC-M2 were only marginally more positive than unlabelled cells used as controls in 
this case (figure 3.10 B). Incubation of cells on Petri dishes at 37 °C for 40 min only 
partly removed myeloid contaminants (figure 3.10 D). We next attempted to isolate 
FDCs by MACS using a modified protocol from Sukumar et al. (Sukumar et al., 2006). 
Briefly, cells were labeled for 1 h with 0.64 μg/ml anti-FDC-M1, followed by 30 min 
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incubation with 5 μg/ml PE-conjugated mouse anti-rat Ig к as secondary antibody. PE-
conjugated mouse anti-rat Ig к labelled cells were isolated using PE-microbeads. 
However, isolated cells with a yield < 1 % were negative for FDC-M1 and FDC-M2 as 
analyzed by flow cytometry (data not shown). To test the specificity of the pull down, 
we sorted cells in presence and absence of FDC-M1, which demonstrated that the sort 
with mAbs against FDC-M1 was unspecific (figure 3.10 E). The use of FcR blocking 
reagent or 10 % mouse serum to block unspecific binding did not improve the 
experimental outcome. 
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Figure 3.10 Summary of FDC isolation from spleen tissue. (A) Experimental procedure for FDC isolation. 
After collagenase digestion released cells were separated by density gradient centrifugation. Cells from 
the upper band of the low density population were retrieved and incubated in a Petri dish at 37 °C for 40 
min. Non-adherent cells were harvested and used subsequently to isolate FDC-M1+ cells by MACS. Low 
density cells isolated in a Percoll gradient contained FDC-clusters as shown by direct microscopic 
observation (B) and were weakly positive for FDC-M1 and FDC-M2 (C). Empty histograms correspond to 
the unlabelled controls. Myeloid contaminants were partially removed after a 40 min adherence step in 
medium at 37 °C and 5 % CO2 (D). Low density cells were magnetic sorted with PE-conjugated mouse 
anti-rat IgG к in the presence (red) and absence (purple) of FDC-M1 as a primary antibody. Overlay 
histogram of the two sorted populations (E).     
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Immune complex labelling 
Since magnetic sorting failed to isolate FDCs we sought to establish alternative isolation 
methods. The retention of immune complexes (IC) on FcR and complement receptors is 
a hallmark of FDCs and has previously been used to determine the purity of FDC 
preparations (Sukumar et al., 2008). While FDCs retained ICs on their surfaces, 
peritoneal macrophages and lymphocytes were shown to phagocytose and clear ICs. 
Internalised and surface exposed ICs were distinguished by secondary antibody 
labelling of exposed ICs (Sukumar et al., 2006).  
By exploiting the unique ability of FDCs to retain ICs surface-bound for long periods, we 
attempted to isolate FDCs from a mixed high density cell population containing B cells, 
DCs and macrophages by pulse-chase experiments. Importantly, 125I-labelled IgG 
complexes were rapidly internalised into mouse macrophages with half-time values 
(t ½) of less than 2 min (Mellman and Plutner, 1984). The question therefore arose 
whether conditions could be established to distinguish FDCs from macrophages, DCs 
and B cells by means of their biological propensity to retain ICs. 
To test this approach isolated macrophages, DCs and B cells were labelled with 
ovalbumine ICs (OVA ICs) at 4 °C for 2 h. After washing excess OVA ICs, cells were kept 
in ice-water to prevent internalization, and then transferred to 37 °C at distinct time 
intervals (1 min, 5 min, 10 min, etc), followed by labelling with a secondary antibody. 
Although ICs are internalised into DCs, B cells and macrophages during a 30 min 
incubation period the fluorescent signal was still very high, possibly due to the 
reappearance of processed IC fragments on the surface of cells or due to unspecific 
binding of OVA ICs (figure 3.11). OVA fluorescence was not significantly reduced by 
extending the incubation period to 1 h (data not shown). Under these conditions the 
identification by flow cytometry of low numbers of FDCs in the low density fraction 
after gradient centrifugation was not possible.  
CHAPTER 3  Results 
 93 
 
 
Figure 3.11 Internalization of OVA immune complexes by B cells (A), DCs (B) and macrophages (C) after 
30 min incubation at 37 °C. Cells were incubated with OVA/anti-OVA for 1 h and then placed into a water 
bath at 37 °C for 30 min (grey). As a control cells were kept on ice throughout the experiment (green). 
Unstained cells were used to locate the viable cells within the first log (pink). 
 
3.5.2 Infectious titres of follicular dendritic cell clusters 
Due to the failed isolation of FDCs by MACS, we investigated whether the contribution 
of FDCs to spleen titres could be assessed using FDC clusters instead. Splenic FDC/B 
clusters isolated from wt and Prnp-/- mice that were inoculated with prions were 
isolated by successive sedimentations at 1 x g in FBS as described in material and 
methods (section 2.2.1). This method was favoured over density gradient 
centrifugation, since it yielded more cell clusters/single cells (ca. 150,000 clusters were 
isolated on average from 10 spleens). Isolated cell clusters were positive for FDC-M1, 
indicating the presence of FDCs (figure 3.12). 
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Figure 3.12 Characterization of follicular dendritic cell clusters. Following extensive collagenase 
digestion of spleen tissue, (A) cell clusters were isolated by 4 successive sedimentations at 1 x g in FBS. 
Isolated cells were cultured on coverslips and examined by fluorescence microscopy for FDC-M1 (B) and 
the corresponding isotype control (C). PE-anti-kappa was used as secondary antibody.    
 
A typical FDC/B cell cluster is composed of 1 to 3 FDCs, 5 to 30 B cells and a few T cells 
attached (Kosco et al., 1992; Liu et al., 1996). To compare infectious titres of FDC 
clusters with previous data of single splenic cells, we determined the protein 
concentration of isolated cells and expressed titres as TCIU/mg of protein. 
Prion titres of FDC clusters at 14 dpi and 30 dpi were compared to those of pDCs and 
NK cells. FDC clusters isolated at 14 dpi showed the highest prion titres and were as 
infectious as pDCs at 30 dpi (table 3.7 A). Of note, the data presented in table 3.7 
corresponds to a single experiment. Nonetheless, under these conditions titres of pDCs 
and NK cells were consistent with previous results. 
Interestingly, infectivity could also be detected in FDC clusters at 3 dpi in the absence 
of prion replication (table 3.7 B).  
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Wild-type mice  Prnp-/- mice 
Cell types 
Log TCIU/mg protein  
Cell types 
TCIU/mg protein 
14 dpi 30 dpi  3 dpi 
pDC 2.8 3.6  Pan DC 8.3 
NK cells 2.6 3.3  B cells u.d 
FDC clusters 3.4 3.6  FDC clusters 11.5 
Table 3.7 Infectivity associated to FDC clusters in wild-type and Prnp-/- mice. Groups of 10 (A) wt or (B) 
Prnp-/- mice were inoculated i.p. with 1 % RML and culled at different time points after inoculation. Since 
accurate cell numbers cannot be obtained for FDC clusters, titres were calculated per mg protein. Each of 
the titres corresponded to one experiment. u.d. undetectable. 
 
3.5.3 Stroma cultures isolated from spleens of scrapie-infected mice do not 
propagate prions ex vivo. 
Stromal cells are considered the main players in prion pathogenesis possibly with a role 
in prion replication (Fraser and Farquhar, 1987; Brown et al., 1999; Kaeser et al., 2001). 
In the previous section we showed that isolated stroma tissue and FDC clusters were 
infectious (table 3.7). We now asked whether freshly isolated stromal cells were able to 
propagate prions ex vivo.  
Long-term stromal cell cultures were established from spleens of adult wild-type mice. 
Following prolonged collagenase digestion of spleens, low density splenic cells were 
separated by density gradient centrifugation as described in material and methods 
(section 2.2.2). These cultures were very heterogeneous when newly established 
(figure 3.13 C), but lost heterogeneity with prolonged culture. At high passage numbers 
cells were mainly fibroblast-like. According to flow cytometric analysis stromal cultures 
contained mainly fibroblasts (podoplanin+) and myeloid cells (CD11c+CD11b+), whereas 
no lymphocytes and NK cells were present (figure 3.13 A). Stromal cells were also 
shown to express PrPC (figure 3.13 B). 
 
A B 
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Figure 3.13 Characterization of stroma cultures. Low density cells, isolated by density centrifugation of 
splenic cells, were collected and cultured in sIMDM at 34 °C and 5 % CO2. Cultures of stroma cells were 
established shortly after isolation. (A) Stroma cultures were characterised by flow cytometry with mAbs 
against podoplanin (fibroblasts), CD11c (DCs) and CD11b (macrophages); CD90, B220 and DX5 are 
specific for lymphocytes and NK cells (i-vi). (B) The expression levels of PrPC were determined on fixed 
stroma cells using biotinylated ICSM35 and FITC-streptavidin as secondary staining. (C) Distinct functional 
areas can be identified in the stromal cultures. Attached to layers of fibroblastic cells myeloid cells are 
continuously formed.  
 
To determine whether newly established splenic stroma cells replicate prions ex vivo, 
129Sv x C57B/6 mice were inoculated i.p. with 1 % RML, culled at 50 dpi and spleens 
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used to generate the stromal cultures. Prion infectivity associated to confluent layers of 
stroma cells was measured by SCEPA at each 1:3 passage. However, infectivity rapidly 
declined during cell splits and no evidence for prion replication of RML prions was 
observed under these conditions (figure 3.14). A replication-competent stroma cell 
type, if present in these cultures, may not be detected in this model where the high cell 
division rates may dilute prions at a greater rate than they are formed and lead to its 
eventual clearance.  
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Figure 3.14 Infectivity of stroma cell cultures after splitting. Stromal cell cultures were established from 
wild-type 129Sv x C57B/6 mice inoculated i.p. with 100 μl of 1 % RML culled at 50 dpi. Infectious titres of 
confluent layer of stroma cells were measured overtime at different each 1:3 passages. Titres are 
expressed per mg protein. 
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3.5 Ex-vivo release of prions from scrapie-infected splenic cells 
The molecular mechanisms involved in the dissemination of prions from the sites of 
infection to lymphoid organs and to peripheral nerves are poorly understood. Several 
immune cells including lymphocytes, DCs and macrophages accumulate prions early in 
the disease process, and extracellular deposits of disease-associated PrP were detected 
in conjunction to FDC membranes (Jeffrey et al., 2000). Several mechanisms for the 
lateral spread of prions including direct cell-to-cell contact (Kanu et al., 2002), prion 
transmission via membrane nanotubes (Gousset et al., 2009) and the release of prions 
via exosomes (Fevrier et al., 2004) have been suggested from several in-vitro studies. 
The in-vivo relevance of these processes has not been demonstrated and poses major 
experimental challenges.  
Exosomes are small vesicles of endosomal origin secreted by all major immune cells, 
including lymphocytes and dendritic cells (reviewed in Thery et al., 2002). Exosomes 
were detected attached to the surface of FDCs in vivo (Denzer et al., 2000). Several cell 
lines secrete infectious exosomes (Fevrier et al., 2004; Vella et al., 2007; Alais et al., 
2008). To test whether the release of exosomes plays a role in vivo we investigated 
whether MACS-isolated immune cells from scrapie-infected animals secrete infectivity 
when cultured ex vivo.  
Freshly isolated B cells, T cells and DCs from scrapie-infected mice were cultured for 
38 h and culture supernatants were sequentially centrifuged according to protocols 
used for the isolation of exosomes (Johnstone et al., 1987; Thery et al., 1999; Wolfers 
et al., 2001). After ultracentrifugation pellets were resuspended in medium and prion 
infectivity was determined by SCEPA. The limited survival of immune cells ex vivo, 
particularly of lymphocytes, may bias the determination of prion secretion where 
prions are released by passive leakage from necrotic cells. To account for the 
contribution of passive leakage of prions from dead cells we cultured cells at 
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atmospheric CO2 at 37 °C in parallel experiments, a treatment that led to rapid necrosis 
of B and T lymphocytes (figure 3.15, table 3.8). In DCs exposure of cells to atmospheric 
CO2 did not suffice to trigger rapid necrosis and we added Triton X-100 at low 
concentrations (0.01 % final) to the culture medium. Exosomes can be released both in 
a constitutive and in a regulated manner (Thery et al., 2002). Exosome release upon B 
cell activation via CD40 and the IL-4 receptor have been reported, suggesting that 
exosome release might depend on external signalling from other immune cells 
(Saunderson et al., 2008). We added IL-4 and LPS to the cultures, a treatment that 
leads to activation of lymphocytes and improved the viability of B cells (figure 3.15).    
A more than 30-fold increase in infectious titres was detected in supernatants of B cells 
and DCs under basal conditions as compared to passive release controls, indicating that 
prions from scrapie infected cells are actively released (table 3.8). Supplementation of 
medium with IL-4, but not with LPS marginally increased prion titres of cell 
supernatants. The titres of released prions constitute about 1 % of the cellular 
infectivity of B cells and DCs. Similar values have been reported for the in-vitro release 
of PrPSc from cell lines using Western blot quantification (Fevrier et al., 2004). To 
examine whether prion secretion in B cells is associated with exosome release we 
resuspended pellets from basal medium and atmospheric CO2 in PBS after 
ultracentrifugation and absorbed aliquots of 3 μl onto EM grids for microscopic analysis 
(figure 3.16). The number of cup-shaped exosomes under basal conditions exceeded 
the number of exosomes during passive leakage by a factor of ten (1.7 ± 1.2 vs. 20.1 ± 
5.7, p < 0.001). Microparticles shed by apoptotic or stimulated cells ranging from 200 to 
1000 nm in diameter (Boulanger et al., 2006; Kiama et al., 2006; Schiller et al., 2008; 
Beyer and Pisetsky, 2010) were infrequently detected under our experimental 
conditions with rates below 0.4 microparticles per count area of 2.82 μm2 with no 
significant difference between basal medium and passive leakage control. 
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Figure 3.15 Effects of culture conditions on the viability of primary cultures of B lymphocytes. IMDM 
supplemented with 10 % FBS, 100 U/ml Pen-Strep, 2mM L-glutamine and 5 μM 2-ME was used as basal 
medium for all cell cultures. As a positive control for the unspecific release of infectivity, B lymphocytes 
were cultured at atmospheric CO2 and 37 °C (A). Representative histograms for B cells, cultured at 5 % 
CO2 and 37 °C in basal medium (B), in the presence of 10 ng/ml IL-4 (C) and with 50 μg/ml LPS (D) are 
shown. Cell viability was assessed by 7-AAD exclusion after 36 h culture. Empty histogram in A 
corresponded to unlabelled cells, this was not included in the other figures for simplicity as it was clear 
the position the unlabelled population.     
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Culture 
Conditions 
B cells T cells ‡Dendritic cells 
Release 
(TCIU/106 
cells ± SE) 
Necrosis 
(%) 
Release 
(TCIU/106 
cells± SE) 
Necrosis 
(%) 
Release 
(TCIU/106 
cells) 
Necrosis 
(%) 
atm. CO2
† 0.2 ± 0.3 100 < 0.1 100 0.2 100 
Basal 5.6 ± 1.0 63 1.1 ± 0.3 48 6.8 51 
basal + IL4 6.3 ± 1.2 34 1.9 ± 0.4 22 n.d. n.d. 
basal + LPS 4.4 ± 0.8 28 n.d. n.d. n.d. n.d. 
Cellular 
infectivity 227 188 898 
†Control incubations were performed in basal medium at atmospheric (atm.) CO2 and 37 °C.  
‡For dendritic cell cultures Triton X-100 was added to a final concentration of 0.01 % in basal 
medium.     
n.d. = not determined 
Table 3.8 Prions are actively released from scrapie-infected splenic cell cultures ex vivo. Fifteen 129Sv x 
C57BL/6 were inoculated i.p. with 100 μl RML I6200 and culled at 60 dpi (a time point at which infectivity 
should have been reached a plateau phase). MACS-isolated B and T lymphocytes were cultured at a 
concentration of 1 Mio/ml in basal medium (IMDM medium, 10 % FBS) in absence or presence of LPS (50 
μg/ml) and IL-4 (10 ng/ml). After 36 h of culture conditioned medium was collected and centrifuged at 
300 x g for 10 min, 5000 x g for 15 min and 10,000 x g for 30 min to remove cells and debris. The 
supernatant was then centrifuged for 2 h at 100,000 x g and the pellet resuspended in PBS, serially 
diluted and infectious titres were determined using the SCEPA. The detection limit of the SCEPA is 0.1 
TCIU/Mio cells and corresponds to 1 positive well out of 12 wells. Titres were calculated by GLM as 
TCIU/106 cell equivalent ± SE of three independent experiments. Data for one single experiment is shown 
for the release of infectivity from DCs. 
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Figure 3.16 Exosomes are released from scrapie-infected B cells ex vivo. Spleens were dissected from 
129/Sv x C57BL/6 mice 30 days after i.p. inoculation with 1 % (w/v) RML I6200. MACS-isolated B 
lymphocytes were cultured under passive leakage (A) and basal (B) conditions essentially as described in 
table 3.8 and tissue culture supernatants were isolated by sequential centrifugation (see materials and 
methods, section 2.3). After centrifugation at 100,000 x g for 2 h pellets were resuspended in PBS, 
absorbed onto carbon-coated grids and negatively stained with 1 % uranyl acetate. Cup-shaped 
exosome-like membrane particles of different sizes (see arrows) are shown in (B). Twenty randomly 
recorded images (surface area: 2.82 μm2) from each condition were counted and the number of 
exosome-like particles (1.7 ± 1.2 (A) and 22.8 ± 6.5 (B) per surface area, p << 0.001) determined in a 
blinded manner. Scale bar: 0.2 μm. 
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DISCUSSION 
Prion colonisation of the lymphoreticular system (LRS) is a hallmark of most prion 
diseases. Stromal and mobile haematopoietic cells participate in different aspects of 
lymphoinvasion, including replication and dissemination of prions. Prion propagation in 
the LRS is a dynamic process that is thought to depend on the interaction and 
contribution of different cell types. While most research focused on the identification 
of the sites of prion replication, in particular the role of follicular dendritic cells (FDC), 
little is known about the role of mobile haematopoietic cells in prion pathogenesis and 
the molecular underpinnings of prion dissemination.  
4.1 Establishment of a method to determine infectious titres of splenic 
cell types involved in prion pathogenesis 
By taking advantage of fast in-vitro infectivity testing (SCEPA) and magnetic activated 
cell sorting (MACS) we established a novel procedure to determine infectious titres of 
seven different cell types, including B cells, T cells, NK cells, DCs, the DC subset pDCs, 
FDC clusters and macrophages during the first weeks after inoculation with prions and 
addressed the dynamics of prion accumulation in the spleen.  
Fluorescence-activated cell sorting (FACS) and MACS are commonly used cell 
separation techniques that yield highly purified cell populations. However, the 
comparatively low throughput of FACS (> 200-fold lower rates than MACS) limits its 
application when large numbers of cells are processed. Using high capacity cell sorting 
by MACS, we developed and optimised a procedure that uses sequential rounds of 
positive selection to isolate different cell types from a pool of splenocytes at high 
purities (figure 3.4) and reasonable processing times, i.e. six cell types were isolated in 
approximate 5 hours (figure 2.1, table 3.3).  
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Comprehensive studies to compare prion titres in candidate cell types at early stages of 
disease have not been performed due to limitations of traditional methods for 
infectivity testing. Animal bioassays, the principal method to determine infectious 
titres, are based on i.c. inoculation of infected samples into indicator mice. Generally, a 
minimum of four to six indicator mice are inoculated i.c. with serially diluted samples 
and infectious titres are calculated from the mortality data. Ethical and economical 
factors greatly limit the number of samples that can be processed by the bioassay. As 
an alternative, immunodetection of PrPSc by Western Blot, a fast in-vitro assay to 
characterise an infectious state, is most frequently used. Defined by its partial 
resistance to protease degradation, PrPSc is a surrogate marker for infectivity but PrPSc 
levels reportedly do not always correlate with prion titres (Sakaguchi et al., 1993; 
Lasmezas et al., 1997; Barron et al., 2007). As a consequence, the bioassay is 
indispensable to confirm prion infectivity. Furthermore, the reduced sensitivity of PrPSc 
detection on Western Blot as compared to infectivity testing limits its use at early 
stages of disease when titres are low. In 129Sv x C57/BL6 mice PrPSc was not detected 
on Western Blot at 3 and 7 dpi in spleens, despite prion titres ranged between 5.4 to 6 
log TCIU/g tissue (figure 3.6). The SCA, on the other hand, is a valuable alternative to 
the bioassay: it is sensitive, detects de-novo formed prions and greatly extends the 
scope of in-vivo assays. Still, the limited permissiveness of N2a cells to different prion 
strains renders animal bioassays yet indispensable. However, the identification of 
prion-susceptible cell lines with broader susceptibilities for mouse-adapted prion or 
natural scrapie strains is of great importance (Vorberg et al., 2004; Mahal et al., 2007; 
Neale et al., 2010) and may further help to limit the requirement of bioassays. 
A more sensitive version of the standard SCA, the SCEPA, was used in our studies to 
determine prion titres and is based on the observation that the proportion of infected 
cells greatly increases by altering the split ratio during passages. After exposure of 
prion-susceptible cells with limiting dilutions of prion-containing samples PrPSc-positive 
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cells could be detected after several passages (Klohn et al., 2003). For example, a 10-9 
dilution of RML (I6200, 9.3 log LD50 units/g brain) resulted in 2 positive wells out of 24, 
corresponding to a remarkable sensitivity of at least 2 LD50 units/ml (table 3.1). Given 
the technical and experimental advantages of the SCEPA, the important question arose 
how the sensitivity of SCEPA compares to that of the bioassay. Comparative endpoint 
titrations showed that the sensitivity of SCEPA was not significantly different from the 
bioassay given the high standard error of the bioassay (table 3.1). However, in 
experiments where prion titres of splenic cell types were determined, SCEPA was about 
one log less sensitive than the bioassay (table 3.2). The particle size of the infectious 
entity may be of particular importance for a cell-based assay, where infectious particles 
have to be internalised for propagation to resume. Differences in the dispersion state 
between homogenates or in the sensitivity to degradation by endogenous proteases 
might explain the reduced sensitivity of SCEPA for the estimation of cell titres as 
compared to tissue titres.  
In conclusion, known advantages of SCEPA, like the short assay duration, the low costs 
and the increased experimental scope clearly outweigh the somewhat lower sensitivity 
levels for prion determination. High throughput prion determination by SCEPA 
therefore renders comparative studies to assess the contribution of specific cells types 
to prion accumulation in the LRS feasible.  
The average number of infectious units in the SCEPA, termed tissue culture infectious 
units (TCIU) can be estimated by assuming that the number of PrPSc positive cells at a 
given dilution follows a Poisson distribution (Klohn et al., 2003; Mahal et al., 2008). 
Inherent to limiting dilution assays, however, the error variance may not be constant 
over the studied range of dilutions (figure 3.1) and thus violate premises of 
conventional linear regression analysis where normally distributed error components 
with constant variance are assumed. This may lead to large errors and compromise the 
estimation of precise infectious titres. To address this problem we here established a 
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generalised linear model (GLM) (Nelder and Wedderburn, 1972) for the estimation of 
robust infectious titres. GLM overcomes restrictions of ordinary regression models 
limited to normally distributed response variables and unify a wide range of probability 
distributions including normal, binomial and Poisson using a flexible iterative method 
for computing maximum likelihood estimates (see appendices). Alternatively, non-
parametric test such Spearman-Karber or Reed-Muench can be used to determine 
prion titres when data is not normally distributed, for example in animal bioassays. 
Where the median lethal dose (LD50) estimate may be a reasonable guess of the titre 
for an assay with no repeats, the corresponding standard error is comparatively high 
(table 3.1 and 3.2) and the more robust statistical method should be considered when 
possible. Nevertheless, the limited experimental scope of bioassays greatly restricts the 
use of statistics and although GLM framework can be equally applied to estimate prion 
titres from bioassays (section 3.2.3) we refrained from using statistical modelling for 
bioassay. The SCEPA yielded very low intra- and inter-assay variability which 
demonstrates the statistical robustness of the assay. The bioassay, on the other hand, 
clearly underperformed and intra- and inter-assay variability for independent assays of 
half to one log was estimated by GLM. However, since the limited experimental scope 
of bioassays greatly restricts the use of statistics we refrained from using statistical 
modelling for bioassay. Since a statistically reliable determination of prion titres is 
fundamental where differences in titres may be critical the SCEPA may be the assay of 
choice, given the cell lines are permissive to the investigated strains (Vorberg et al., 
2004; Mahal et al., 2007; Neale et al., 2010).  
4.2 Role of antigen presenting cells in prion sequestration  
The exceptional rate of prion propagation in lymphoid organs provides evidence of 
highly coordinated processes for the dissemination and replication of prions. In only 3 
days after inoculation, infectivity increased by nearly 3 logs in spleens of wt mice as 
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compared to replication-deficient mice (figure 3.6 A). A titre of 2.5 log TCIU/g spleen 
was still detected in spleens of Prnp-/- at 3 dpi, indicating that PrP-independent 
mechanisms are involved in the sequestration and transport of prions from the sites of 
infection to lymphoid organs. A similar titre was found after i.c. inoculation of RML 
brain homogenate into Prnp-/- mice (Bueler et al., 1993). Remarkably, in the absence of 
prion replication, infectivity accumulated preferentially in DCs and macrophages as 
compared to lymphocytes (table 3.4), thus supporting a role of antigen-presenting cells 
in prion sequestration. Macrophages and DCs are found in peripheral tissues and in 
strategic sites of lymphoid organs, the marginal zone and sinuses, where they can 
efficiently scavenge the lymphatic fluid, internalise and present antigens to T cells (Junt 
et al., 2008) (see figure 4.1). Interestingly, in addition to macrophages and DCs, FDC 
clusters were also infectious in replication-deficient Prnp-/- mice (table 3.7 B). FDCs are 
immobile stromal cells confined to B cell follicles that retain antigens in the form of 
immune complexes at the plasma membrane (Batista and Harwood, 2009). 
Macrophages in the subcapsular sinus and medulla of lymph nodes were shown to 
capture and present antigens to B cells in the follicles (Carrasco and Batista, 2007; Junt 
et al., 2007). The delivery of antigen to FDCs seems to be mediated by marginal and 
follicular B cells (Batista and Harwood, 2009). The presence of prions in FDC clusters in 
the absence of prion replication indicates that mechanisms for antigen delivery to FDCs 
are used by prions. B cells are indispensable for prion propagation irrespective of their 
PrP status (Klein et al., 1998). In addition to their trophic support of FDCs via TNF/LT 
signalling, B cells may be involved in other mechanisms such as transfer of prions to 
FDCs. Migrating DCs mediate an active transport of antigens from the peripheral tissues 
into lymph nodes. Alternatively, antigens can be transported passively by lymph into 
lymph nodes, or by blood into the spleen, where large antigens require active transport 
by resident cells and small antigens (> 70 kDa) are transported directly to T cell areas in 
the lymphoid organs through the conduit system that consists of collagen fibres 
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enclosed by the stromal fibroblastic reticular cells and resident DCs scattered that 
sample the lymphatic fluid (Sixt et al., 2005) (see figure 4.1).   
 
Figure 4.1 Areas of antigen encounter in lymphoid organs. Antigens are transported to the lymph nodes 
via afferent lymphatics (A) or to the spleen via blood (B) by cell-mediated or non cell-mediated 
mechanisms. Migrating DCs that capture antigen in peripheral tissues can enter the lymph nodes for 
antigen presentation to T cells. Soluble antigen can be captured by macrophages and DCs in the sinuses 
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or access the T cell areas directly through the FRC conduit in case it is smaller than 70 kDa. Reproduced 
from the Nature Reviews, Junt, T. et al., 2008, Vol 8, pp 764-775 (Junt et al., 2008). 
 
Although several studies have addressed the time-dependent distribution of infectivity 
in different lymphoid organs following inoculation of prions, only a few studies 
determined the levels of infectivity attributable to different cell types (Eklund et al., 
1967; Kimberlin and Walker, 1979; Kimberlin and Walker, 1980; Kimberlin and Walker, 
1989a). Early studies showed high infectious titres preferentially associated to cells 
with low buoyant densities, comprising enriched fractions of blast cells, macrophages 
and dendritic cells (Lavelle et al., 1972; Kuroda et al., 1983). More recently, high 
infectious titres have been detected in highly purified fractions of DCs (Aucouturier et 
al., 2001) and lymphocytes (Raeber et al., 1999a). Nonetheless, these studies are 
restricted to one or two cell types and a particular time point. We here characterised 
the time-dependent accumulation of prions in splenic cell types during the first month 
after inoculation, as prion titres reached plateau levels in the spleen.  
Prions accumulated in all investigated cell types at 3 dpi and increased rapidly over 
time by about 20-50 fold between 3 and 30 dpi (table 3.5) consistent with an increase 
of infectivity in spleen tissue. The highest prion levels were determined in a subset of 
DCs, plasmacytoid DC (pDC) where prion titres exceeded the levels of B cells and T cells 
by about 7-fold. High titres were also associated to NK cells, a type of lymphocytes with 
about 3-fold higher infectious titres than conventional lymphocytes (figure 3.7).  
High prion titres of DCs have previously been reported for the 139A prion strain 
(Aucouturier et al., 2001). DCs are specialized antigen presenting cells that form a 
heterogeneous group of cells with distinct highly regulated trafficking patterns and 
functions. Their contribution to prion pathogenesis to date is unknown. DCs were 
suggested as mobile carriers for prions from the gut to draining lymph nodes after oral 
inoculation of mice with prions (Huang et al., 2002; Huang and MacPherson, 2004). A 
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role of DCs in neuroinvasion was inferred from studies showing that i.v. inoculation of 
prion-infected DCs into Rag-/- mice sufficed to transmit disease into the CNS 
(Aucouturier et al., 2001). However, this observation was not confirmed by other 
experimental approaches (Rybner-Barnier et al., 2006; Raymond et al., 2007). DCs were 
detected in the CNS of mice inoculated i.p. with the mouse-adapted GSS strain 
(Rosicarelli et al., 2005). Recent evidence suggests that DCs migrate into the CNS in 
other neuropathological conditions. PDCs, for example are the major CNS-infiltrating 
cells during experimental autoimmune encephalomyelitis (EAE) (Bailey-Bucktrout et al., 
2008). Of note, prion disease progression was accelerated by induction of EAE in 
scrapie infected mice (Friedman-Levi et al., 2007).  
PDCs are specialized DCs that produce natural type 1 inferferon (IFN-1) in response to a 
viral infection. They are clearly distinct from conventional DCs in regards to their 
localisation in the lymphoid organs, their antigen presenting properties, their migration 
pathways and physiological function. Together with NK cells, pDCs are essential 
mediators of the antiviral immune response via IFN-1 signalling (Villadangos and Young, 
2008). The number of pDCs is highly variable among mouse strains, with the 129Sv 
strain showing several fold higher numbers than most other strains (Asselin-Paturel et 
al., 2003). Reportedly less endocytotic than conventional DCs (Grouard et al., 1997; 
Dalgaard et al., 2005), pDCs were initially considered to have a minor role in antigen 
uptake and presentation. Nonetheless, it has been show that pDCs efficiently 
internalise soluble proteins such as OVA in vivo and in vitro (Villadangos and Young, 
2008). Other reports showed that pDCs internalise latex-beads and apoptotic debris 
(Ochando et al., 2006; Hoeffel et al., 2007). Of interest, PrPSc was internalised by bone 
marrow derived pDCs in vitro (Rybner-Barnier et al., 2006). Due to their high infectious 
titres we investigated whether pDCs are replication-competent. However, expression 
of PrPC, a pre-requisite for the replication of prions (Bueler et al., 1993), was not 
detected in freshly isolated splenic pDCs (figure 3.8). This result was in agreement with 
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previous reports where PrPC expression in pDCs was undetectable or low as compared 
to conventional DCs (Rybner-Barnier et al., 2006; del Hoyo et al., 2006). Although prion 
replication-competence of cells cannot be predicted on the basis of its level of PrP 
expression (Vorberg et al., 2004), pDCs seem a priori a poor candidate for a role in 
prion replication.  
Further investigations will be required to elucidate why pDCs accrue prions more 
effectively than lymphocytes. Preliminary experiments showed that proteasomal 
degradation of prion-infected pDCs was not significantly different from uninfected 
control pDCs (data not shown). PDCs are located in the T cell rich areas of lymph nodes 
associated to high endothelial venules (HEV). In the spleen pDCs are found scattered in 
the T cells areas or periarteriolar lymphoid sheath (PALS), in the red pulp and rarely in 
the marginal zone. Their distribution differs from conventional DCs which are 
predominantly found in the marginal zone and outer PALS, but not in the red pulp of 
the spleen (Asselin-Paturel et al., 2005). Interestingly, highly infectious NK cells are also 
found in areas of antigen entry to lymphoid organs, mostly in the red pulp of spleen 
and inside the blood sinuses together with macrophages. In the lymph nodes, NK cells 
are found in the paracortex with HEVs and in the medulla within lymphatic sinuses 
(Gregoire et al., 2007). Whether the distinct localisation of pDCs and NK cells and their 
presence in the red pulp or in the paracortex is related to their high prion titres has to 
be further investigated. A bidirectional cross-talk between pDCs and NK cells has 
recently been shown to play a key role in host defence (Gerosa et al., 2005; Lucas et al., 
2007). 
Another important characteristic of pDCs that distinguishes them from conventional 
DCs are their migration pathways. While conventional DCs travel from the peripheral 
tissues via afferent lymphatics to draining lymph nodes, most reports support the 
notion that pDC enter the lymph nodes via the bloodstream through the high 
endothelial venules (HEV) (Randolph et al., 2008). Albeit at low numbers, pDCs are 
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found in peripheral tissues, mainly in the intestine and kidneys, but are also found in 
skin and liver, under steady-state conditions (Villadangos and Young, 2008). Whether 
pDCs, like conventional DCs, actively transport antigens from the periphery to lymphoid 
organs is not clear, but it raises the possibility that prions could be transported by pDCs 
to lymph nodes via HEVs. In a preliminary experiment where pDCs are depleted by 
treatment with mPDCA-1 antibodies before and after inoculation with prions, lower 
prion titres were detected in mesenteric lymph nodes of pDC-depleted mice as 
compared to control mice while no differences were found in spleens (table 3.6). The 
entry of cells into lymph nodes via HEV is a highly regulated process that is mainly 
restricted to lymphocytes under steady-state conditions (Young, 1999). If the transport 
of prions into the lymph nodes via the haematogenous route was more efficient than 
via the lymph (e.g. depending on the inoculation route), the entry of infectious pDCs via 
HEVs could contribute to the titre in lymph nodes. However, no evidence for a 
predominant role of the haematogenous route was found, in agreement with previous 
reports (Raeber et al., 1999a). 
Despite high prion titres in the spleen at early stages of disease, only very low titres 
were reported in blood, mainly associated to buffy coat fractions and plasma (Brown et 
al., 1998; Aguzzi and Glatzel, 2006). No infectivity was detected in peripheral blood 
leukocytes (PBL) (Raeber et al., 1999a) or in our study in blood-borne pDCs (table 3.5), 
regardless of the relatively high prion titres associated to these cells in spleen tissue, 
indicating that recirculation of prion-infected cells is clearly restricted. Indeed, 
recirculation of cells between blood and tissues via efferent lymphatics is mainly 
limited to lymphocytes, in particular to T cells and to a lesser degree to B cells (25 % 
recirculate) (Young, 1999). Recirculation of NK cells is also restricted under steady-state 
conditions (Gregoire et al., 2007). Although small numbers of DCs in the thoracic duct 
which drains into the vascular system gives evidence for DC recirculation, this is very 
infrequent under steady-state conditions (Bonasio and von Andrian, 2006). Even 
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though prion infectivity is detected in various tissues, including lung, liver, spleen, 
salivary glands and in blood as early as 30 min after i.p. inoculation (Millson et al., 
1979), prion propagation is restricted to the LRS. A rapid decrease of prion titres in 
non-permissive tissues may be a result of rapid degradation and transport to the LRS, 
respectively. The intriguing question why prions remain largely confined in replication-
competent lymphoid organs remains unanswered, and the highly coordinated 
interactions between haematopoietic and stromal cells may hold the answer. A clear 
evidence for this hypothesis comes from chronic inflammatory conditions, like systemic 
lupus erythematosus, autoimmune diabetes, nephritis and pancreatitis where prions 
propagate in non-permissive tissues (Heikenwalder et al., 2005). Under these 
conditions, a mobilisation of immune cells to sites of infection could also transport 
prion cargo from lymphoid to affected organs. Although it is generally accepted that 
misfolded PrP does not stimulate an immune response in the host (Kasper et al., 1982), 
recent reports showed abnormal germinal centre reactions in the spleen of scrapie 
infected mice manifested by an increased maturation of follicular B cells observed at 
70 dpi and endstage (McGovern et al., 2004). Variations in the number of CD21+ B cells 
in lymph nodes of prion-infected sheep as compared to controls were also reported 
(Eaton et al., 2007; Eaton et al., 2009). We therefore examined whether we could 
changes in splenic B cell subsets between scrapie and control mice are detectable at 
preclinical stages. However, the ratios of CD21hi CD23- marginal zone B cells and 
CD21int CD23hi follicular B cells were unchanged between scrapie-infected and mock-
infected mice at 30, 80 and 100 dpi in the 3 spleen analysed per time point (figure 3.9). 
In summary, a novel procedure to characterise the time-dependent accumulation of 
prions in the spleen showed that DCs, in particular pDCs, and the lymphocyte subset, 
NK cells, sequester prions efficiently. In Prnp-/- mice in the absence of prion replication 
highest titres were associated to FDC clusters, DCs and macrophages which highlights 
the ability of these cells to sequester prions independently of their PrP status. Most 
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challenging for a further progress in our understanding of lymphatic prion colonisation 
will be to better characterise the contribution of each cell type. With the method 
reported here changes in the cell tropism of prion after experimental interventions 
could be determined in a uniquely comprehensive manner. While most of the previous 
reports that addressed the role of specific cells by depletion experiments fell short of 
controlling and preventing a fast replenishment of depleted haematopoietic cell types 
by blood-borne precursors, it will be highly valuable to revisit experiments that focused 
on the depletion of pDCs (our study), the depletion of DCs (Raymond et al., 2007; 
Cordier-Dirikoc and Chabry, 2008), macrophages (Beringue et al., 2000) and FDCs 
(Mabbott et al., 2000; Montrasio et al., 2000) using the established procedures and 
investigate how specific cell types affect the cell tropism of prion accumulation and 
whether changes in prion titres of major splenic cell types are correlated to disease 
onset. Based on our experimental evidence for a role of DCs in prion sequestration, it 
will be interesting to revisit the activation of the innate immune system using specific 
toll-like receptors (TLR) agonist that showed a protective effect on prion disease (Sethi 
et al., 2002). TLRs which are involved in the recognition of conserved features of a wide 
range of invading pathogens are expressed on different DC subtypes, e.g. TLR9 and 
TLR7 are expressed on pDCs whereas TLR2, TLR4, TLR7 and TLR8 are expressed in mDCs 
(Larsson et al., 2004). The reported immunopathology after multi-dose regimen with 
CpG oligonucleotides in the Sethi study (Heikenwalder et al., 2004a) greatly 
discouraged further attempts to stimulate the immune system. With the development 
of new generation adjuvants with reduced toxicity and increased potency like clinical 
approved “Monophosphoryl Lipid A” (MPL), a low-toxicity version of LPS (Mata-Haro et 
al., 2007) or the TLR7 ligand “imiquimod” (Wang et al., 2005), it may now be possible to 
revisit the stimulation of the innate immune system to assess the cell tropism of prion 
accumulation.  
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4.3 Contribution of the stroma compartment to prion pathogenesis 
To complement the characterisation of the kinetics of prion accumulation in 
haematopoietic cell types during early pathogenesis, a major goal was to determine 
infectivity associated to the stromal compartment. FDCs have received the most 
attention of all stromal cell types and are discussed as main candidates for a role in 
prion replication (Mabbott and Bruce, 2002). Abnormal PrP deposits accumulate on the 
surface of FDCs (Jeffrey et al., 2000), but infectious titres have not been reported yet. 
The isolation of a highly purified FDC fraction by magnetic sorting has been described 
previously (Sukumar et al., 2006). Standard protocols for the isolation of FDCs include 
immunisation and irradiation of mice to boost the number of germinal centres and to 
deplete lymphocytes, respectively (Kosco-Vilbois et al., 1993). Both procedures are 
likely to have an impact on prion titres (Dickinson et al., 1978; Fraser and Farquhar, 
1987) and were not considered for our purposes. Using SCEPA for titre determination 
and MACS for the specific isolation of FDCs we attempt to determine infectious titres of 
FDCs. However, under these conditions any attempt to isolate FDCs (e.g. cell 
enrichment in a Percoll gradient before MACS isolation) failed. Once the collagen 
matrix of spleen tissue is digested, FDCs readily form clusters that can be detected by 
microscopy after enrichment (figure 3.10 C). We suppose that major problems during 
MACS isolation of FDCs are related to the limited access of antibodies to epitopes on 
the surface of FDCs which may be buried by B cells or to the low expression levels of 
FDC-M1 in the non-activated state (Rao et al., 2002). By diverting from standard 
protocols such as immunisation and irradiation of mice, the performance of FDC-M1 
used in the MACS isolation may drop significantly. Alternative isolation strategies based 
on the unique ability of FDCs to retain immune complexes (IC) on their surfaces were 
envisaged. Although an internalisation of ICs by antigen presenting cells was observed 
after 30 min incubation, fluorescence did not decrease to control levels and therefore 
failed the identification of low numbers of positive FDCs (figure 3.11).  
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Given the failure to obtain purified FDCs, enrichment protocols for FDC/B cell clusters 
were used to determine infectious titres. FDC-M1+ FDC/B cell clusters were isolated 
based on their higher sedimentation rate at 1 x g in FBS as compared to single cells of a 
heterogeneous cell population (figure 3.12). Titres of FDC clusters were determined in 
Prnp-/- mice at 3 dpi and in wt mice at 14 and 30 dpi and compared to prion titres of 
other cell subsets from the same pool of cells (table 3.7). In the absence of prion 
replication FDC yielded a titre of 12 TCIU/mg protein and 8 TCIU/mg protein for 
pan DCS, whereas B cells were not infectious which clearly indicating that FDCs retain 
infectivity at early phases after inoculation (table 3.7 B). In wt mice FDC clusters were 
about 1 log more infectious than pDCs and NK cells at 14 dpi (table 3.7 A).  However, 
since an unknown number of infectious B cells are aggregated with FDCs in wt mice the 
actual infectious titre of FDCs remains unknown. 
Recent reports have suggested that other stromal cells, like mesenchymal and 
fibroblastic reticular cells could support prion propagation in the absence of FDCs 
(Heikenwalder et al., 2008). Several fibroblastic cell lines were found to be prion-
permissive and propagate prions at high rates (Vorberg et al., 2004). In agreement with 
previous results (Clarke and Kimberlin, 1984), the stromal compartment of the spleen 
contains high prion titres about 7 logs/g tissue (section 3.5.2) and therefore the 
interesting question arose whether primary cultures of stroma cells isolated from 
scrapie-infected mice retain the ability of prion propagation ex vivo. Splenic stromal cell 
cultures can be readily generated within 4 days after isolation from wt mice and form a 
heterogeneous population of cells. Stromal cultures consisted mainly of podoplanin+ 
fibroblasts and expressed PrPC, but also contained macrophages and DCs (figure 3.13).  
However, evidence of prion replication was not observed in splenic stroma cultures and 
the endogenous infectivity decreased rapidly with subsequent passages (figure 3.14). 
The high rate of cell division of stroma cultures ex vivo may dilute out propagating 
prions by repeated cell division (Bosque and Prusiner, 2000) or activate pathways that 
CHAPTER 4  Discussion 
 118 
degrade prions as reported by for myeloid cells (Luhr et al., 2002; Rybner-Barnier et al., 
2006).  
4.4 Ex-vivo release of prions from scrapie-infected splenic cells 
Prions colonise the LRS of 129Sv x C57BL/6 mice at very early stages of the disease at 
compelling rates. Infectivity is found in lymphocytes, macrophages, DCs and FDC 
clusters (table 3.4 and table 3.7), indicating the existence of very efficient mechanisms 
for the lateral spread of prions. We here present the first evidence for an active 
secretion of prions from immune cells isolated from scrapie-infected mice (table 3.8). 
Infectivity released into the culture medium was pelleted by high speed centrifugation 
and pellets were highly enriched in exosome-like particles (figure 3.16).  
Since the limited viability of immune cells in culture could bias the determination of an 
active prion secretion, we maximised passive leakage of infectivity in control cultures 
by incubating cells at atmospheric CO2 (data shown for B cells in figure 3.15). We 
showed that infectious titres of cell culture supernatants of B cells and DCs exceeded 
those of passive leakage controls by about 30-fold, T cells also secreted infectivity 
although at lower amounts (table 3.8). Interestingly, the release of prions from scrapie-
infected B cells was associated with the secretion of exosome-like vesicles (figure 3.16). 
The limited amount of infectivity released into the culture medium, i.e. 1-2 % of the 
cellular infectivity, hampered the characterisation on Western Blot of the 100,000 x g 
pellets for the presence of exosomal markers such as CD63, Tsg 101, Alix-1 or flotillin 
(Simons and Raposo, 2009). Still, exosomes can be distinguished from other secreted 
microvesicles or apoptotic blebs by their characteristic cup-shape morphology and 
smaller size 30-100 nm (Mathivanan et al., 2010). Other mechanisms that such as cell-
to-cell contact (Kanu et al., 2002) or the recently proposed transfer of prions along 
nanotubes (Gousset et al., 2009) could also contribute to the spread of prions.  
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While the exact site of prion replication is under debate, PrPSc can be detected on the 
plasma membrane, recycling endosomes, late endosomes and lysosomes (McKinley et 
al., 1991; Arnold et al., 1995; Marijanovic et al., 2009). Exosomes are small vesicles of 
endosomal origin formed by invagination of the membrane of late endosomes or 
multivesicular bodies (MVB) (van Niel et al., 2006). Fusion of MVBs with the plasma 
membrane release exosomes to the extracellular medium. The integration of prions 
into exosomes would enable the transfer of prion infectivity without the requirement 
for direct cell-to-cell contact and the question arises whether exosome secretion has a 
role for the spread of infectivity in vivo. Haematopoietic and stromal cells with a role in 
the propagation and dissemination of prions were shown to either secrete exosomes or 
act as recipients for exosomes. Macrophages, DCs, T cells and B cells were shown to 
secrete exosomes in culture (Thery et al., 2002; Vella et al., 2008b) and exosomes are 
found in vivo associated to the membrane of FDCs (Denzer et al., 2000). Interestingly, 
studies showed that B cell-derived exosomes, but not those from other cell types, bind 
to FDCs surfaces in vitro (Denzer et al., 2000). B cell exosomes might also bind to 
extracellular matrix (ECM) proteins (collagen I and fibronectin) and activated fibroblasts 
as suggested in other in vitro studies (Clayton et al., 2004). In addition, reports for the 
secretion of PrPC in primary  cultures of cortical (Faure et al., 2006) and PrPC in 
exosomes isolated from the CSF from sheep (Vella et al., 2008a), suggest that 
exosomes might also be implicated in the dissemination in the CNS.  
The involvement of exosomes in pathological processes is not a new concept (Gould et 
al., 2003). Retroviruses were shown to hijack the exosomal machinery to bud out of the 
cells, e.g. HIV-1 infected exosomes released into the medium by DCs mediated the 
infection of T cells (Wiley and Gummuluru, 2006). Interestingly, the release of 
prion-infected exosomes is enhanced by retroviral infection, suggesting that both 
pathogens use common pathways for exocytose the cells (Leblanc et al., 2006). 
Exosome release has also been linked to other neurodegenerative diseases such 
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Alzheimer and Parkinson’s diseases where Aβ peptides and α-synuclein can be secreted 
in exosomes (Rajendran et al., 2006; Emmanouilidou et al., 2010).  
4.5 Concluding remarks 
The work presented here forms the basis for a novel approach to the unresolved 
question of the mode of prion dissemination which I hope may inspire further attempts 
to investigate the dynamics of prion spread. The statistical power and short duration of 
in-vitro infectivity assays are convincing arguments to pursue and refine cell-based 
infectivity assays to better understand early stages of prion dissemination. High prion 
titres in pDCs, a cell type that so far has not caught the attention in the field due to 
undetectable levels of PrPc, the substrate for protein misfolding may contribute to the 
appreciation of PrP-independent processes, like prion sequestration and dissemination. 
Where seminal work in the last two decades helped to elucidate the molecular 
mechanisms of prion replication in the LRS, the role of antigen-presenting cells 
remained dubious. A better characterisation of the migration pathways of antigen-
presenting cells may be critical to understand prion colonisation of the LRS. The 
compelling rate of prion accumulation in the LRS at early stages after infection gives 
evidence to a complex network of interaction between a variety of cell types. Of 
importance the active release of prions by immune cells may represent the same 
molecular pathways that are usurped by viruses, and future experiments will show 
whether gene perturbation of members of the ESCRT complex which prevents the 
release of virions will also inhibit prion release. Give the important role of antigen-
presenting cell in the innate immune system the stimulation of Toll-like receptors as 
postexposure prophylaxis is definitely an avenue worth pursuing. 
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APPENDICES 
1. Determination of infectious titres using a GLM regression 
GLMs constitute a class of statistical models that relate observations to linear 
combinations of predictor variables. GLM regression can be applied to a wide range of 
probability distributions that belong to the ‘exponential family’ by the use of a common 
method for computing maximum likelihood estimates. In a standard linear model E [Yj], 
the expected value of the jth response Yj, is equal to a linear combination of explanatory 
variables xj1, xj2, …, xjk, termed the linear predictor η j, thus: 
E (Yj) = α + β1 xj1 + β2 xj2 + … βk xjk + ej = η j + ej  ej ~ iid N (θ,σ2) (1) 
In a GLM the link function g, a monotone differentiable function, defines the 
relationship between the linear predictor η and the mean of the distribution, thus: 
g (E(Y)) = η       (2) 
The inverse of the link function is g-1 (η) = E (Y). For prion titre determinations by 
endpoint assays the response variable Yj, the number of positive wells at the jth 
dilution, is linked to the dilution by a complementary log-log transformation 
g (Pj) = log (-log (1-Pj)), where Pj = E (Yj/nj) and nj is the number of independent 
infections at the jth dilution, via 
g (Pj) = α + β xj       (3) 
where xj is the jth log dilution, α is the log mean number of infectious units and β is the 
slope parameter. Other link functions for the binomial model used for titre 
determination by bioassay are the logit function g (Pj) = log (Pj/(1-Pj)) and the probit 
function  g (Pj) = Φ-1 (Pj). The probit function is the inverse cumulative distribution 
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function of the standard normal distribution. These three common link functions and 
their inverses are summarised below: 
 
 g (P) g-1 (η) 
Complementary log-log Log (-log (P)) 1-exp [-exp(η)] 
Logit Log (P/(1–P) 1/(1+exp(-η)) 
Probit Φ-1 (P) Φ (η) 
 
The complementary log-log transformation arises naturally for in-vitro titres since if the 
number of infected cells follows a Poisson distribution then the proportion 1 - Pj of 
negative wells at dilution cj is equal to exp (-mcj), where m is the mean number of 
infectious units per volume, which is equivalent to relation (3) with β = 1.  
The parameters α and β, where α is the log mean infectious units and β the regression 
slope, are estimated by the method of maximum likelihood. For a given probability 
distribution specified by f (yi|θ) and observations y1, y2…yn the log likelihood function 
for θ is 
l(θ) = log L(θ) = ∑ log f(yi|θ)       (4) 
where L(θ) is the likelihood function. 
2. R code for the determination of infectious titres from SCEPA by GLM 
The observed proportions of negative wells from multiple serial dilution of RML 
(Table A1) can be fitted using a GLM with binomial family complementary log-log link 
by the R function: 
fit <-glm(cbind(positive,negative)~logdil, data = ori, family=binomial (link="cloglog")) 
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This code fits a ‘saturated’ model in which the slope parameter β is arbitrary. The 
‘reduced’ model with a unit slope, corresponding to a Poisson model for the number of 
infected cells, can be fitted using the following R function: 
fit <-glm(cbind(positive,negative)~1, data = ori, offset=logdil, family=binomial 
(link="cloglog")) 
To check the fit of a GLM with binomial family and complementary log-log link we can 
use the analysis of deviance, a method to test whether the discrepancies between the 
observed and predicted values lie within an acceptable limit of experimental error. 
 
 Saturated model Reduced model 
Slope 0.9608 1 
Standard error 0.0969 - 
Degrees of freedom 30 31 
Residual deviance 26.82 26.99 
AIC 106.88 105.04 
 
The estimated value for the slope factor β is 0.9608 ± 0.0969. This allows us to test the 
null hypothesis that the true slope is one using the Wald test. The p-value 
corresponding to the z-score (0.9608-1)/ 0.0969 is 0.69, indicating no evidence of a 
departure from an underlying Poisson distribution for the number of infected cells. 
Alternatively we can test this hypothesis using the likelihood ratio test statistic (LRS), 
LRS = -2 [log(Ls)/log(Lr)] = -2log(Ls) + 2log(Lr) = Ds - Dr 
where Ls and Lr are the maximised likelihoods under the saturated and reduced models, 
respectively, and Ds and Dr are the respective deviances. The LRS approximately follows 
a Chi-square distribution with degrees freedom equal to the difference in the number 
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of parameters fitted in the two models, here one.  Here LRS = 26.99 - 26.82 = 0.17, 
giving a p-value of 0.68, approximately the same as the p-value from the Wald test.  
The reduction of AIC is a further indication of the superiority of the reduced model. 
In both the saturated and reduced models, the residual deviance, which is a measure of 
how much the data deviates from the model, is lower than the residual degrees of 
freedom, indicating that the data are not overdispersed in relation to an underlying 
binomial distribution. The reduced model yielded an estimated titre of 8.63 ± 0.03 
logTCIU/g brain for eight technical repeats of serially diluted RML I6200 brain 
homogenate. 
3. Determination of infectious titres from bioassay using a GLM 
To establish a GLM for titre determination on bioassay we performed six independent 
endpoint titrations by bioassay using brain homogenate RML I6200 as inoculum 
(Table A2). The proportion of positive wells and the fitted proportions from the 
complementary log-log and probit models are shown in figure 3.3. The complementary 
log-log and probit models resulted in estimated titres of 8.54 ± 0.54 and 8.71 ± 0.53, 
respectively. A corresponding titre with a slightly higher standard error (8.66 ± 0.80 log 
LD50 units/g brain) was calculated by the Spearman Karber method and a GLM was 
used for all subsequent titre determinations. For a direct comparison of the sensitivity 
levels between SCEPA versus bioassay we therefore repeated an endpoint titration 
experiment. 
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Table A1: In-vitro endpoint titration of RML I6200  
Serially diluted RML I6200 was transferred onto layers of prion-susceptible PK1 cells 
and the number of positive and negative wells was determined by SCEPA as described 
in materials and methods (section 2.2.3). Data represent eight technical assay repeats 
of serially diluted homogenate. 
 
  Repeats SCEPAs 
Dilution Wells 1 2 3 4 5 6 7 8 
10-7 positive 12 12 12 12 12 12 12 12 
negative 0 0 0 0 0 0 0 0 
6.6x10-8 positive 12 12 12 12 12 12 12 12 
negative 0 0 0 0 0 0 0 0 
3.3x10-8 positive 11 12 12 12 11 10 12 10 
negative 1 0 0 0 1 2 0 2 
10-8 positive 9 6 8 9 7 8 8 6 
negative 3 6 4 3 5 4 4 6 
6.6x10-9 positive 6 4 4 4 3 7 6 4 
negative 6 8 8 8 9 5 6 8 
3.3x10-9 positive 4 6 2 4 1 4 3 3 
negative 8 6 10 8 11 8 9 9 
10-9 positive 0 3 0 1 0 2 2 0 
 negative 12 9 12 11 12 10 10 12 
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Table A2: Serial mouse bioassays to determine endpoint titres of 
RML I6200 
Five aliquots of RML brain homogenate I6200 (10 %, w/v) were each serially diluted 
1:10 into uninfected CD1 brain homogenate (10 %, w/v) and kept frozen at -80 °C until 
further use. For mouse bioassays, groups of six Tga20 mice were inoculated 
intracerebrally with 30 μl brain homogenates and attack rates and scrapie incubation 
times were determined. Data represent five independent bioassays. 
 
  Repeats SCEPAs 
Dilution Scrapie 1 2 3 4 5 
10-5 sick 6 6 6 5 6 
healthy 0 0 0 0 0 
10-6 sick 6 6 6 3 5 
healthy 0 0 0 1 1 
10-7 sick 3 3 3 4 3 
healthy 3 3 3 2 2 
10-8 sick 0 0 1 2 1 
healthy 5 6 5 3 5 
10-9 sick 1 0 0 0 1 
healthy 5 5 6 6 5 
 
 
 
